<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/215C8CB9-38B2-495F-89F4-21D4414B80C6"><gtr:id>215C8CB9-38B2-495F-89F4-21D4414B80C6</gtr:id><gtr:name>University of California, Berkeley</gtr:name><gtr:address><gtr:line1>University of California, Berkeley</gtr:line1><gtr:line2>191 University Hall</gtr:line2><gtr:postCode>CA 94720</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/64051F00-08A4-4F1B-A637-A32A284A3C3B"><gtr:id>64051F00-08A4-4F1B-A637-A32A284A3C3B</gtr:id><gtr:name>Institute for Research on the Spinal Cord and Brain (IRME)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/52423922-8331-4312-A996-E4734BB4D688"><gtr:id>52423922-8331-4312-A996-E4734BB4D688</gtr:id><gtr:name>Utrecht University</gtr:name><gtr:address><gtr:line1>PO Box 80125</gtr:line1><gtr:line2>3508 TC Utrecht</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/40D8250C-C708-4AD7-B244-058E48DD3B31"><gtr:id>40D8250C-C708-4AD7-B244-058E48DD3B31</gtr:id><gtr:name>Peter MacCallum Cancer Centre</gtr:name><gtr:address><gtr:line1>Smorgon Family Bldg</gtr:line1><gtr:line2>St Andrew's place</gtr:line2><gtr:line4>Melbourne</gtr:line4><gtr:line5>VIC, 3002</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/08B7FC3F-6505-4352-AE46-A91D9163A583"><gtr:id>08B7FC3F-6505-4352-AE46-A91D9163A583</gtr:id><gtr:name>College of Medicine, Biological Sciences and Psychology</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/61B5E6D6-02CE-4BD5-A1E9-773F980F3F74"><gtr:id>61B5E6D6-02CE-4BD5-A1E9-773F980F3F74</gtr:id><gtr:name>Syntaxin</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5786934C-E914-4DBB-B39D-6D5A4B56DA13"><gtr:id>5786934C-E914-4DBB-B39D-6D5A4B56DA13</gtr:id><gtr:name>Lamellar Biomedical Ltd</gtr:name><gtr:address><gtr:line1>Caledonian House</gtr:line1><gtr:line2>Phoenix Crescent</gtr:line2><gtr:line3>Strathclyde Business Park, Bellshill</gtr:line3><gtr:postCode>ML4 3NJ</gtr:postCode><gtr:region>Unknown</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/0517AC0E-EF12-4F19-A6DD-6406FF2123A2"><gtr:id>0517AC0E-EF12-4F19-A6DD-6406FF2123A2</gtr:id><gtr:name>Life Technologies</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/41A6F529-3374-4F2A-8350-29C571A8C235"><gtr:id>41A6F529-3374-4F2A-8350-29C571A8C235</gtr:id><gtr:name>European Commission (EC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4D256583-980C-4154-8084-3B1D98B6FB27"><gtr:id>4D256583-980C-4154-8084-3B1D98B6FB27</gtr:id><gtr:name>Stem Cell Technologies</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/FAE32A25-51D3-49EF-998F-281B3A47C212"><gtr:id>FAE32A25-51D3-49EF-998F-281B3A47C212</gtr:id><gtr:name>Helmholtz Association of German Research Centres</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/8A3BD264-2E36-4E02-AC7E-BE7EB07BE6EE"><gtr:id>8A3BD264-2E36-4E02-AC7E-BE7EB07BE6EE</gtr:id><gtr:name>Multiple Sclerosis Society</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/75E77BF3-29B4-4699-9CD9-223230E8A463"><gtr:id>75E77BF3-29B4-4699-9CD9-223230E8A463</gtr:id><gtr:name>Babraham Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3DF2F8DD-33A5-44A1-81D7-347A6C2FBDC8"><gtr:id>3DF2F8DD-33A5-44A1-81D7-347A6C2FBDC8</gtr:id><gtr:name>Stanford University</gtr:name><gtr:address><gtr:line1>450 Serra Mall</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5F5BAD7F-AA15-49ED-A877-007C91F81657"><gtr:id>5F5BAD7F-AA15-49ED-A877-007C91F81657</gtr:id><gtr:name>Stem Cells for Safer Medicines (SC4SM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/57150975-2FFC-442F-A99E-ABD25A46F8D2"><gtr:id>57150975-2FFC-442F-A99E-ABD25A46F8D2</gtr:id><gtr:name>Pasteur Institute, Paris</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/040001EB-7CD7-4B8C-998C-7097FA7B9B98"><gtr:id>040001EB-7CD7-4B8C-998C-7097FA7B9B98</gtr:id><gtr:name>Mount Sinai Hospital (Canada)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/01D89904-1CB7-4802-B20D-595C38C69416"><gtr:id>01D89904-1CB7-4802-B20D-595C38C69416</gtr:id><gtr:name>Primorigen Biosciences</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/56443A66-B72D-4164-A2AE-F16898367510"><gtr:id>56443A66-B72D-4164-A2AE-F16898367510</gtr:id><gtr:name>Uppsala University</gtr:name><gtr:address><gtr:line1>PO Box 256</gtr:line1><gtr:postCode>SE-751 05</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F1AA9E37-A42D-4929-9C6D-583BF2C93F1F"><gtr:id>F1AA9E37-A42D-4929-9C6D-583BF2C93F1F</gtr:id><gtr:name>University of South Australia</gtr:name><gtr:address><gtr:line1>Frome Rd</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/8218E276-85FA-4CD5-86AA-232A830B5037"><gtr:id>8218E276-85FA-4CD5-86AA-232A830B5037</gtr:id><gtr:name>University of Texas at San Antonio</gtr:name><gtr:address><gtr:line1>One UTSA Circle</gtr:line1><gtr:line4>San Antonio</gtr:line4><gtr:line5>TX 78249-1644</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/67B34D05-3A52-4A09-8FF9-F2398D60E246"><gtr:id>67B34D05-3A52-4A09-8FF9-F2398D60E246</gtr:id><gtr:name>University of Surrey</gtr:name><gtr:address><gtr:line1>Registry</gtr:line1><gtr:line2>Stag Hill</gtr:line2><gtr:line4>Guildford</gtr:line4><gtr:line5>Surrey</gtr:line5><gtr:postCode>GU2 7XH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/232FE897-4F2F-40BD-A92F-28CE006F8158"><gtr:id>232FE897-4F2F-40BD-A92F-28CE006F8158</gtr:id><gtr:name>San Raffaele del Monte Tabor Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5F600791-9929-4BAE-9186-DB9F207BD7C1"><gtr:id>5F600791-9929-4BAE-9186-DB9F207BD7C1</gtr:id><gtr:name>McGill University</gtr:name><gtr:address><gtr:line1>845 Sherbrooke Street W</gtr:line1><gtr:line4>Montreal</gtr:line4><gtr:line5>Quebec, H3A 2T5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/46DB0EB7-3DE7-4E45-BFC0-2E7255E49A4B"><gtr:id>46DB0EB7-3DE7-4E45-BFC0-2E7255E49A4B</gtr:id><gtr:name>Bristol-Myers Squibb</gtr:name><gtr:address><gtr:line1>Bristol-Myers Squibb</gtr:line1><gtr:line2>311 Pennington Rocky Hill Road</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5EDA5EBD-A5D5-4551-ABDF-22BBC5993EE3"><gtr:id>5EDA5EBD-A5D5-4551-ABDF-22BBC5993EE3</gtr:id><gtr:name>Royal Netherlands Academy of Arts and Sciences (KNAW)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D317E8C1-3E16-4E48-8AAC-E2A0961F5299"><gtr:id>D317E8C1-3E16-4E48-8AAC-E2A0961F5299</gtr:id><gtr:name>Erasmus University Medical Center</gtr:name><gtr:address><gtr:line1>PO Box 2040</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5B860555-9C7A-4AA5-990F-47C80B4BBECD"><gtr:id>5B860555-9C7A-4AA5-990F-47C80B4BBECD</gtr:id><gtr:name>Cellartis AB</gtr:name><gtr:address><gtr:line1>Arvid Wallgrens Backe 20</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4057964E-5005-47AC-BA09-4238296AC886"><gtr:id>4057964E-5005-47AC-BA09-4238296AC886</gtr:id><gtr:name>Multicell Technologies</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/680A2524-B8AD-4E19-ACD2-3EECFCC5DAF1"><gtr:id>680A2524-B8AD-4E19-ACD2-3EECFCC5DAF1</gtr:id><gtr:name>Hull York Medical School</gtr:name><gtr:address><gtr:line1>John Hughlings Jackson Building</gtr:line1><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>Royal (Dick) School of Veterinary Scienc</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/215C8CB9-38B2-495F-89F4-21D4414B80C6"><gtr:id>215C8CB9-38B2-495F-89F4-21D4414B80C6</gtr:id><gtr:name>University of California, Berkeley</gtr:name><gtr:address><gtr:line1>University of California, Berkeley</gtr:line1><gtr:line2>191 University Hall</gtr:line2><gtr:postCode>CA 94720</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/64051F00-08A4-4F1B-A637-A32A284A3C3B"><gtr:id>64051F00-08A4-4F1B-A637-A32A284A3C3B</gtr:id><gtr:name>Institute for Research on the Spinal Cord and Brain (IRME)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/52423922-8331-4312-A996-E4734BB4D688"><gtr:id>52423922-8331-4312-A996-E4734BB4D688</gtr:id><gtr:name>Utrecht University</gtr:name><gtr:address><gtr:line1>PO Box 80125</gtr:line1><gtr:line2>3508 TC Utrecht</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/40D8250C-C708-4AD7-B244-058E48DD3B31"><gtr:id>40D8250C-C708-4AD7-B244-058E48DD3B31</gtr:id><gtr:name>Peter MacCallum Cancer Centre</gtr:name><gtr:address><gtr:line1>Smorgon Family Bldg</gtr:line1><gtr:line2>St Andrew's place</gtr:line2><gtr:line4>Melbourne</gtr:line4><gtr:line5>VIC, 3002</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/08B7FC3F-6505-4352-AE46-A91D9163A583"><gtr:id>08B7FC3F-6505-4352-AE46-A91D9163A583</gtr:id><gtr:name>College of Medicine, Biological Sciences and Psychology</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/61B5E6D6-02CE-4BD5-A1E9-773F980F3F74"><gtr:id>61B5E6D6-02CE-4BD5-A1E9-773F980F3F74</gtr:id><gtr:name>Syntaxin</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5786934C-E914-4DBB-B39D-6D5A4B56DA13"><gtr:id>5786934C-E914-4DBB-B39D-6D5A4B56DA13</gtr:id><gtr:name>Lamellar Biomedical Ltd</gtr:name><gtr:address><gtr:line1>Caledonian House</gtr:line1><gtr:line2>Phoenix Crescent</gtr:line2><gtr:line3>Strathclyde Business Park, Bellshill</gtr:line3><gtr:postCode>ML4 3NJ</gtr:postCode><gtr:region>Unknown</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/0517AC0E-EF12-4F19-A6DD-6406FF2123A2"><gtr:id>0517AC0E-EF12-4F19-A6DD-6406FF2123A2</gtr:id><gtr:name>Life Technologies</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/41A6F529-3374-4F2A-8350-29C571A8C235"><gtr:id>41A6F529-3374-4F2A-8350-29C571A8C235</gtr:id><gtr:name>European Commission (EC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4D256583-980C-4154-8084-3B1D98B6FB27"><gtr:id>4D256583-980C-4154-8084-3B1D98B6FB27</gtr:id><gtr:name>Stem Cell Technologies</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/FAE32A25-51D3-49EF-998F-281B3A47C212"><gtr:id>FAE32A25-51D3-49EF-998F-281B3A47C212</gtr:id><gtr:name>Helmholtz Association of German Research Centres</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/8A3BD264-2E36-4E02-AC7E-BE7EB07BE6EE"><gtr:id>8A3BD264-2E36-4E02-AC7E-BE7EB07BE6EE</gtr:id><gtr:name>Multiple Sclerosis Society</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/75E77BF3-29B4-4699-9CD9-223230E8A463"><gtr:id>75E77BF3-29B4-4699-9CD9-223230E8A463</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3DF2F8DD-33A5-44A1-81D7-347A6C2FBDC8"><gtr:id>3DF2F8DD-33A5-44A1-81D7-347A6C2FBDC8</gtr:id><gtr:name>Stanford University</gtr:name><gtr:address><gtr:line1>450 Serra Mall</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5F5BAD7F-AA15-49ED-A877-007C91F81657"><gtr:id>5F5BAD7F-AA15-49ED-A877-007C91F81657</gtr:id><gtr:name>Stem Cells for Safer Medicines (SC4SM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/57150975-2FFC-442F-A99E-ABD25A46F8D2"><gtr:id>57150975-2FFC-442F-A99E-ABD25A46F8D2</gtr:id><gtr:name>Pasteur Institute, Paris</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/040001EB-7CD7-4B8C-998C-7097FA7B9B98"><gtr:id>040001EB-7CD7-4B8C-998C-7097FA7B9B98</gtr:id><gtr:name>Mount Sinai Hospital (Canada)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/01D89904-1CB7-4802-B20D-595C38C69416"><gtr:id>01D89904-1CB7-4802-B20D-595C38C69416</gtr:id><gtr:name>Primorigen Biosciences</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/56443A66-B72D-4164-A2AE-F16898367510"><gtr:id>56443A66-B72D-4164-A2AE-F16898367510</gtr:id><gtr:name>Uppsala University</gtr:name><gtr:address><gtr:line1>PO Box 256</gtr:line1><gtr:postCode>SE-751 05</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F1AA9E37-A42D-4929-9C6D-583BF2C93F1F"><gtr:id>F1AA9E37-A42D-4929-9C6D-583BF2C93F1F</gtr:id><gtr:name>University of South Australia</gtr:name><gtr:address><gtr:line1>Frome Rd</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/8218E276-85FA-4CD5-86AA-232A830B5037"><gtr:id>8218E276-85FA-4CD5-86AA-232A830B5037</gtr:id><gtr:name>University of Texas at San Antonio</gtr:name><gtr:address><gtr:line1>One UTSA Circle</gtr:line1><gtr:line4>San Antonio</gtr:line4><gtr:line5>TX 78249-1644</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/67B34D05-3A52-4A09-8FF9-F2398D60E246"><gtr:id>67B34D05-3A52-4A09-8FF9-F2398D60E246</gtr:id><gtr:name>University of Surrey</gtr:name><gtr:address><gtr:line1>Registry</gtr:line1><gtr:line2>Stag Hill</gtr:line2><gtr:line4>Guildford</gtr:line4><gtr:line5>Surrey</gtr:line5><gtr:postCode>GU2 7XH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/232FE897-4F2F-40BD-A92F-28CE006F8158"><gtr:id>232FE897-4F2F-40BD-A92F-28CE006F8158</gtr:id><gtr:name>San Raffaele del Monte Tabor Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5F600791-9929-4BAE-9186-DB9F207BD7C1"><gtr:id>5F600791-9929-4BAE-9186-DB9F207BD7C1</gtr:id><gtr:name>McGill University</gtr:name><gtr:address><gtr:line1>845 Sherbrooke Street W</gtr:line1><gtr:line4>Montreal</gtr:line4><gtr:line5>Quebec, H3A 2T5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/46DB0EB7-3DE7-4E45-BFC0-2E7255E49A4B"><gtr:id>46DB0EB7-3DE7-4E45-BFC0-2E7255E49A4B</gtr:id><gtr:name>Bristol-Myers Squibb</gtr:name><gtr:address><gtr:line1>Bristol-Myers Squibb</gtr:line1><gtr:line2>311 Pennington Rocky Hill Road</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5EDA5EBD-A5D5-4551-ABDF-22BBC5993EE3"><gtr:id>5EDA5EBD-A5D5-4551-ABDF-22BBC5993EE3</gtr:id><gtr:name>Royal Netherlands Academy of Arts and Sciences (KNAW)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D317E8C1-3E16-4E48-8AAC-E2A0961F5299"><gtr:id>D317E8C1-3E16-4E48-8AAC-E2A0961F5299</gtr:id><gtr:name>Erasmus University Medical Center</gtr:name><gtr:address><gtr:line1>PO Box 2040</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5B860555-9C7A-4AA5-990F-47C80B4BBECD"><gtr:id>5B860555-9C7A-4AA5-990F-47C80B4BBECD</gtr:id><gtr:name>Cellartis AB</gtr:name><gtr:address><gtr:line1>Arvid Wallgrens Backe 20</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4057964E-5005-47AC-BA09-4238296AC886"><gtr:id>4057964E-5005-47AC-BA09-4238296AC886</gtr:id><gtr:name>Multicell Technologies</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/680A2524-B8AD-4E19-ACD2-3EECFCC5DAF1"><gtr:id>680A2524-B8AD-4E19-ACD2-3EECFCC5DAF1</gtr:id><gtr:name>Hull York Medical School</gtr:name><gtr:address><gtr:line1>John Hughlings Jackson Building</gtr:line1><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/6E21A7D6-BE0F-45B5-9AAD-25FE1CE982B1"><gtr:id>6E21A7D6-BE0F-45B5-9AAD-25FE1CE982B1</gtr:id><gtr:firstName>Charles</gtr:firstName><gtr:surname>ffrench-Constant</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0700711"><gtr:id>CD8E9B79-5DA7-4A39-8749-C3317B5EDCC7</gtr:id><gtr:title>Application for Centre for Regenerative Medicine</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700711</gtr:grantReference><gtr:abstractText>A revolutionary new medical Centre, the Scottish Centre for Regenerative Medicine, has been opened at the University of Edinburgh. The Centre aims to develop new treatments for disease through research into stem cells.
?Stem cells? are master cells that have the ability either to multiply themselves or form the specialised cells that make up different tissues. Scientists and doctors believe that understanding how stem cells behave will lead to development of new treatments. The new treatments may involve replacing cells in the patient that have been damaged by disease. In other cases it may be possible to identify drugs that are able to make the patient?s own cells carry out the repair. 
Stem cells will also be used in testing new drugs. At present the effect of new drugs is measured in tests with animals or with cells from animals. Sometimes the results are misleading because of differences between humans and animals. By using human cells for tests, scientists will reduce the number of animals that are used and the frequency with which misleading results cause expensive delays. 
Scientists at SCRM have identified a number of diseases which to work on first. These are chosen because Edinburgh scientists lead the field in studying these diseases and stem cells may genuinely help to treat them. One aim is to be able to repair bone more effectively, especially to assist in hip repair. Other research will try to develop treatments to repair the nervous system, in diseases such as Multiple Sclerosis or Motor Neuron Disease. At present many patients with liver disease die before a suitable organ becomes available for transplantation. Stem cells may provide an alternative means of treatment. Stem cells may be used to repair the immune system and give back the patient?s ability to fight infections. In the longer term other programmes will address issues concerned with cancer, diabetes, heart disease and damage to the eye.
SCRM will provide high class training for the basic scientists and the doctors needed for the new treatments to be applied safely and effectively. Finally, SCRM will work hard to ensure commercialisation of its research and work closely with biotechnology and pharmaceutical companies. 
Together these activities in the new Centre will help to position the UK at the forefront of international stem cell science, provide important new opportunities for development of novel therapies and create well paid jobs in the UK.</gtr:abstractText><gtr:technicalSummary>Research with stem cells offers important opportunities for the development of new treatments for human disease. These treatments may involve replacement of cells that are lost or damaged, either by transplantation of stem cells into patients or administration of new drugs to stimulate the patients own tissues to repair the damage. Alternatively drugs may be administered to prevent the damage from occurring. Stem cell research is also expected to lead to improved and accelerated drug screening and reduce the number of animals that are sued for this purpose. 

To address this immense opportunity, the Scottish Centre for Regenerative Medicine (SCRM) is being created at the University of Edinburgh by bringing together the world leading research groups presently in the Institute for Stem Cell Research in the School of Biological Science with those in the Medical School who have clinical interests in stem cell research and therapy. Uniquely in the UK, SCRM will cover the full spectrum of research that is required to move stem cell research from the bench to the bedside. Research will range from studies of the basic mechanisms that maintain stem cell populations both in people and in the laboratory, through projects to establish reliable procedures for the production of cells suitable for their clinical purpose to clinical trials with stem cells, their derivatives or new drugs. 

In the first place, the new knowledge arising from research at SCRM will be applied in developing treatments for repair of the nervous system, liver, bone and cartilage or reconstruction of the immune system and blood systems. These are chosen because of Edinburgh?s research strengths in these areas and their suitability for these treatments. In the longer term other programmes will address issues concerned with cancer, diabetes, heart disease and damage to the eye. To support these programmes, SCRM will develop technologies required to advance this research, including modification of procedures established in the laboratory to make them suitable for large scale clinical use. SCRM will also have an active programme to ensure commercialisation of its research and develop collaborative research programmes with biotechnology and pharmaceutical companies. To support the critically needed expansion of this field SCRM will provide training for basic scientists and clinicians at all career levels. 

Together the activities in the new Centre will help to position the UK at the forefront of international stem cell science and provide important new opportunities for development of new therapies.</gtr:technicalSummary><gtr:fund><gtr:end>2013-04-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1668831</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cellartis AB</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Cellartis-Petter Bjorquist</gtr:description><gtr:id>3EBE30DB-1874-4151-BFA4-11C4D76051A1</gtr:id><gtr:impact>Work in progress</gtr:impact><gtr:partnerContribution>research output</gtr:partnerContribution><gtr:piContribution>Petter Bjorquist</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pasteur Institute, Paris</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Institut Pasteur, Paris-Investigation of pluripotency factor function in epigenetic mechanisms of X-inactivation.</gtr:description><gtr:id>79BEDDF8-7926-4170-8B3C-5F9BCB165D9A</gtr:id><gtr:impact>Navarro, P., Chambers, I., Karwacki-Neisius, V., Chureau, C., Morey, C., Rougelle, C. and Avner, P. (2008) Direct molecular coupling of Xist regulation and pluripotency. Science, 321, 1693-1695 Cited in Faculty of 1000: http://www.f1000biology.com/article/id/1124285/evaluation &amp;amp; Navarro, P., Oldfield, A., Legoupi, J., Festuccia, N., Dubois, A., Attia, M., Rougeulle, C., Chambers, I. and Avner, P. Molecular coupling of Tsix regulation and pluripotency. Accepted at Nature.</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Begun approximately 2005. Investigation of pluripotency factor function in epigenetic mechanisms of X-inactivation. Supported by funding from WT &amp;amp; EuroSyStem.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission (EC)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:department>EC FP6 Collaborative Projects</gtr:department><gtr:description>EU FP6 Consortium Project 'ESTOOLS' -'Recombination Tools and Genetic Switches'</gtr:description><gtr:id>FCE6960D-F5BE-4309-803B-290DB1F8A5E1</gtr:id><gtr:impact>NK</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Human ES Cell Genetic Manipulation - 'Recombination Tools and Genetic Switches'. EU involving collaborations with groups in Bonn (Frank Edenhofer), Dresden (Konstantinos Anastassiadis), Sheffield (Peter Andrews). Entirely EU funded but involved expertise and participation FP6 Consortium Project 'ESTOOLS' [August 2006 - August 2010] of MRC Centre Human ES Cell Facility Manager (Judy Flertcher) for work done in Edinburgh University.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Multiple Sclerosis Society</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK Multiple Sclerosis Society funded Centre for Repair in Cambridge.</gtr:description><gtr:id>665865AF-7E02-458B-BD02-2DE5BF678807</gtr:id><gtr:impact>Paper submitted to Nature Neurosci (and sent out for review)</gtr:impact><gtr:partnerContribution>UK Multiple Sclerosis Society funded Centre for Repair in Cambridge. Co-PI responsible for target discovery based on array profiling remyelination and inflammation</gtr:partnerContribution><gtr:piContribution>UK Multiple Sclerosis Society funded Centre for Repair in Cambridge. With Franklin, Compston, Chandran, Fawcett, Spillantini (all Cambridge originally, Chandran now moved to Edinburgh) Co-PI responsible for target discovery based on array profiling remyelination and inflammation</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Utrecht University</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Bernard Roelen (Utrecht)-Investigation of Nanog expression in testes.</gtr:description><gtr:id>D7B6E8E4-FA95-448D-86BB-931FF021EF68</gtr:id><gtr:impact>Kuijk, E.W., de Gier, J., Chuva de Sousa Lopes, S.M., Chambers, I., van Pelt, A.M.M., Colenbrander, B., Roelen, B.A.J. (2010) A distinct pattern in mammalian testes indicates a conserved role for Nanog in spermatogenesis. PloS One, 5, e10987.</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Investigation of Nanog expression in testes. Supported by funding from WT.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CIR, University of Edinburgh -Shared PhD student on Tregs in CNS remyelinations, with PhD studentship from the SCRM.</gtr:description><gtr:id>3C847DD5-27CA-4485-AEEC-1A2E60CC2D1E</gtr:id><gtr:impact>NK</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Shared PhD student on Tregs in CNS remyelinations, with PhD studentship from the SCRM.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Oxford Stem Cell Institute</gtr:department><gtr:description>Analysis of use of alternative promoters for Runx1</gtr:description><gtr:id>5FBE327A-674C-425D-A97A-CDC0645E4F5C</gtr:id><gtr:impact>This collaboration resulted in publication: T. Bee, et al. (2009). Alternative Runx1 promoter usage in mouse developmental hematopoiesis. Blood Cells Mol. Dis. 43, 3542</gtr:impact><gtr:partnerContribution>Use of different Runx1 promoters is related to production of short and long Runx1 isoforms</gtr:partnerContribution><gtr:piContribution>We provided our Runx1 reactivatable knockout mouse model to Dr Marella de Bruijn</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Babraham Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Stem Cell Sciences UK Ltd</gtr:department><gtr:description>CB Collaboration with Stem Cell Sciences</gtr:description><gtr:id>82222255-0175-4F36-9A5D-65E551AEFFF6</gtr:id><gtr:impact>NK</gtr:impact><gtr:piContribution>BBSRC CASE studentship (entered under further funding)</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Texas</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>M. D. Anderson Cancer Center</gtr:department><gtr:description>CB Collaboration with MD Anderson Cancer Centre</gtr:description><gtr:id>C8670ED7-E02D-4F47-9B1F-AA72736A40D5</gtr:id><gtr:impact>NK</gtr:impact><gtr:partnerContribution>Development of joint research project.</gtr:partnerContribution><gtr:piContribution>Development of joint research project. Participation in closed symposia for award holders.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC-Differentiation of hepatocytes from hES and hiPS cells Dave Hay (CRM) and Gareth Sullivan &amp;amp; Ian Wilmut (CRM),</gtr:description><gtr:id>BEF6F22E-4B59-43C6-ADBB-BB4752602ACF</gtr:id><gtr:impact>NK</gtr:impact><gtr:partnerContribution>several publications</gtr:partnerContribution><gtr:piContribution>Differentiation of hepatocytes from hES and hiPS cells Dave Hay (CRM) and Gareth Sullivan &amp;amp; Ian Wilmut (CRM),</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Helmholtz Association of German Research Centres</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Helmholtz Centre for Infection Research (HZI)</gtr:department><gtr:description>Hellmholtz, Munich-Live cell imaging analysis of pluripotent cells.</gtr:description><gtr:id>BCAD84D5-FA84-45D3-BE55-206402AB5835</gtr:id><gtr:impact>Grant funded; 2010-2013 HFSP Programme grant (IC, lead PI) &amp;quot;A microfluidic, small molecule approach to perturbation of the pluripotency transcription network.&amp;quot; I.Chambers, T.Schroeder, T.Wandless &amp;amp; L.Lee. $1,200,000 US</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Live cell imaging analysis of pluripotent cells. Supported by funding from HFSP.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Further development of proteomic and molecular markers of muscle loss.</gtr:description><gtr:id>9AE4C07B-D4C1-4AE6-8596-ADCFDF6F748A</gtr:id><gtr:impact>Contract under discussion</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>further development of proteomic and molecular markers of muscle loss.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC-Tissue scaffolds - Richard Black, University of Strathclyde</gtr:description><gtr:id>9ABD8FA0-8475-43EF-98BC-852254503C56</gtr:id><gtr:impact>application in progress</gtr:impact><gtr:piContribution>Tissue scaffolds - Richard Black, University of Strathclyde</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mount Sinai Hospital (Canada)</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>Samuel Lunenfeld Research Institute</gtr:department><gtr:description>Single vector reprogramming system</gtr:description><gtr:id>402770CE-007C-4F1C-BAED-C431EB6DA6A5</gtr:id><gtr:impact>Using the system we published two Nature papers.</gtr:impact><gtr:partnerContribution>By combining their piggyBac system and our single vector system we developped a system with which we can generate non-genetically modified induced pluripotent stem cells.</gtr:partnerContribution><gtr:piContribution>We developed a system with which we can generate non-genetically modified induced pluripotent stem cells</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>College of Medicine, Biological Sciences and Psychology</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Biochemistry</gtr:department><gtr:description>Leicester-analysis of cytoskeletal function in myelination,</gtr:description><gtr:id>8DE14543-A72E-4946-A0BA-159CB25BD9D4</gtr:id><gtr:impact>NK</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>David Critchley (Leicester), analysis of cytoskeletal function in myelination, 2008, work ongoing</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Cambridge University-Biology of Nanog.</gtr:description><gtr:id>617D851D-C88B-4713-81CB-A9B1F237AB21</gtr:id><gtr:impact>Silva, J., Nichols, J., Theunissen, T.W., Guo, G., van Oosten, A.L., Barrandon, O., Wray, J., Yamanaka, S., Chambers, I. and Smith, A. (2009) Nanog is the gateway to the pluripotent ground state. Cell 138, 722-737.</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Biology of Nanog. Supported by funding from WT.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Syntaxin</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Syntaxin-basis for exocytosis blocking project in 2010, treatment for secretory disorders</gtr:description><gtr:id>0C7922DB-5B60-42B7-A3E7-1D815FF512AD</gtr:id><gtr:impact>NK</gtr:impact><gtr:partnerContribution>NK</gtr:partnerContribution><gtr:piContribution>basis for exocytosis blocking project in 2010, treatment for secretory disorders</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Primorigen Biosciences</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Primorigen -Chuck Ohler</gtr:description><gtr:id>C0243D3C-7592-43D2-8844-669CA167F008</gtr:id><gtr:impact>Work in progress</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Chuck Ohler</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>University College London-Humphrey Hodgson</gtr:description><gtr:id>C1ECBBC5-72CB-4EE4-92D1-23015C947421</gtr:id><gtr:impact>Work in progress</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Humphrey Hodgson</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC -Development of multi-modal contrast agents for imaging and gene delivery, funding from BHF and Wellcome Trust - Carmel Moran, Keith Fox, Dave Newby, Ian Marshall, John Mullins, etc (UoE), 2005,2008.</gtr:description><gtr:id>4F9A8D51-1467-4B33-B1FA-2D4B299BA0B7</gtr:id><gtr:impact>NK</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Development of multi-modal contrast agents for imaging and gene delivery, funding from BHF and Wellcome Trust - Carmel Moran, Keith Fox, Dave Newby, Ian Marshall, John Mullins, etc (UoE), 2005,2008.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC funded project to enhance axon regeneration in spinal cord injury.</gtr:description><gtr:id>48AC48BF-3C67-4A84-A0B0-432F2C606C3D</gtr:id><gtr:impact>J Neurosci paper in 2009</gtr:impact><gtr:partnerContribution>MRC funded project to enhance axon regeneration in spinal cord injury. Co-PI responsible for integrin engineering</gtr:partnerContribution><gtr:piContribution>MRC funded project to enhance axon regeneration in spinal cord injury. With Fawcett (Cambridge) Co-PI responsible for integrin engineering</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>McGill University</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>AM collaboration with McGill University</gtr:description><gtr:id>41A79CE9-563F-4DBB-87E9-75C81EB34E59</gtr:id><gtr:impact>NK</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>NK</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of California</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>University of California, Berkeley</gtr:department><gtr:description>UC, Berkeley-Bio-engineering applications for the study of pluripotent cells.</gtr:description><gtr:id>EFF0EC3D-5179-43F4-9C58-9DB4FA941CEB</gtr:id><gtr:impact>Grants funded; 2010-2013 HFSP Programme grant (IC, lead PI) &amp;quot;A microfluidic, small molecule approach to perturbation of the pluripotency transcription network.&amp;quot; I.Chambers, T.Schroeder, T.Wandless &amp;amp; L.Lee. $1,200,000 US &amp;amp; 2009 Foreign &amp;amp; Commonwealth Office, UK-US Stem Cell Collaboration Development Award. I.Chambers and L. Lee (UC Berkeley) &amp;pound;2,782</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Bio-engineering applications for the study of pluripotent cells. Supported by funding from UK FCO &amp;amp; HFSP.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>University of Edinburgh-Novel gene trap vectors.</gtr:description><gtr:id>25125B59-7FCB-4CAA-B6C2-FDADA196D088</gtr:id><gtr:impact>Tsakiridis, A., Tzouanacou, E.,Rahman, A., Colby, D., Axton, R., Chambers, I., Wilson, V., Forrester, L. and Brickman, J. (2009) Expression-independent gene trap vectors for random and targeted mutagenesis in embryonic stem cells. Nucleic Acids Res. 37, e129.</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Novel gene trap vectors. Supported by funding from WT.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>San Raffaele del Monte Tabor Foundation</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Milan_ analysis of neuregulin function in myelination</gtr:description><gtr:id>76BEE431-8D45-4E15-A96B-0F43AC8A2220</gtr:id><gtr:impact>paper in preparation</gtr:impact><gtr:partnerContribution>research output</gtr:partnerContribution><gtr:piContribution>Carla Taveggia (Milan) analysis of neuregulin function in myelination, 2008,</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Erasmus University Rotterdam (Erasmus Universitair Medisch Centrum EUR)</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Erasmus, Rotterdam-Investigation of protein-protein interactions in pluripotent cells.</gtr:description><gtr:id>940D1F00-76C6-4A97-8F8D-D47ED29BCC04</gtr:id><gtr:impact>van den Berg, D.L.C., Zhang, W., Yates, A., Engelen, E., Takacs, K., Bezstarosti, K., Demmers, J. Chambers, I. and Poot, R.A. (2008) The Estrogen Related Receptor Beta interacts with Oct4 to positively regulate Nanog gene expression. Mol. Cell. Biol., 28, 5986-5995 &amp;amp; van den Berg, D.L.C., Snoek, T., Mullin, N.P., Yates, A., Bezstarosti, K., Demmers, J. Chambers, I. and Poot, R.A. (2010) An Oct4-centred protein interaction network in embryonic stem cells. Cell Stem Cell, 6, 369-381.</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Begun approximately 2005. Investigation of protein-protein interactions in pluripotent cells. Supported by funding from WT.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>screening polymer libraries using hESC-derived hepatic endoderm</gtr:description><gtr:id>4FA42C01-0345-4F87-9217-2C614759EFF7</gtr:id><gtr:impact>Compounds were identified that provide effective support for human hepatic endoderm</gtr:impact><gtr:partnerContribution>Collaboration in screening polymer libraries using hESC-derived hepatic endodermProvided library of compoounds</gtr:partnerContribution><gtr:piContribution>screening polymer libraries using hESC-derived hepatic endoderm</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC-MRC clinical training fellowship (2008) for Janet Kung [CRM liver grouping]. co-supervisors Stuart Forbes (CRM) &amp;amp; Paddy Hadoke (CVS)</gtr:description><gtr:id>A857E0DA-0491-4D1E-B169-7D1BDF260EC6</gtr:id><gtr:impact>NK</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>MRC clinical training fellowship (2008) for Janet Kung [CRM liver grouping]. co-supervisors Stuart Forbes (CRM) &amp;amp; Paddy Hadoke (CVS)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Chemistry Edinburgh</gtr:department><gtr:description>screening polymer libraries using hESC-derived hepatic endoderm</gtr:description><gtr:id>868CEBDC-3B2C-4DB7-8B56-B8CC518474D2</gtr:id><gtr:impact>Compounds were identified that provide effective support for human hepatic endoderm</gtr:impact><gtr:partnerContribution>Collaboration in screening polymer libraries using hESC-derived hepatic endodermProvided library of compoounds</gtr:partnerContribution><gtr:piContribution>screening polymer libraries using hESC-derived hepatic endoderm</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lamellar Biomedical Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Lamellar Biomedical Ltd.-Consultancy, progress toward clinical trials, treatment for secretory disorders.</gtr:description><gtr:id>29B368B3-45FE-4AFA-9391-B27FEBE56B68</gtr:id><gtr:impact>CSO bid being asembled</gtr:impact><gtr:partnerContribution>CSO bid being asembled</gtr:partnerContribution><gtr:piContribution>Consultancy, progress toward clinical trials, treatment for secretory disorders.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Uppsala (Uppsala universitet)</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Neuroscience Institute Uppsala</gtr:department><gtr:description>Role of Runx1 in differentiation of doundary cap neural crest stem cell differentiation</gtr:description><gtr:id>4B37BBD5-1BB0-4760-B690-8100BC83BC89</gtr:id><gtr:impact>Publication in prestigeous stem cell magazine: Aldskogius, et al., &amp;quot;Regulation of Boundary Cap Neural Crest Stem Cell Differentiation after Transplantation&amp;quot; Stem Cells 27, 15921603</gtr:impact><gtr:partnerContribution>We learned how our Runx1 tetracyclineinducible constructs work in primary cells</gtr:partnerContribution><gtr:piContribution>Provided Runx1 (short and long isoforms) inducible constructs and transgenic mice</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC National Institute for Medical Research (NIMR)</gtr:department><gtr:description>AM Collaboration with NIMR</gtr:description><gtr:id>5E522A62-A964-4190-859A-6104F9019BAA</gtr:id><gtr:impact>NK</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>NK</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC National Institute for Medical Research (NIMR)</gtr:department><gtr:description>CB Collaboration with NIMR</gtr:description><gtr:id>F3D31293-A666-4F53-9E04-7805DD7CCD53</gtr:id><gtr:impact>NK</gtr:impact><gtr:piContribution>NK</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Erasmus University Rotterdam (Erasmus Universitair Medisch Centrum EUR)</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>CB Collaboration with Erasmus Rotterdam</gtr:description><gtr:id>9EB64689-9A5B-4592-AE37-99244E86633D</gtr:id><gtr:impact>NK</gtr:impact><gtr:piContribution>NK</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>University of Edinburgh-using zebrafish to examine molecular mechanisms of myelination</gtr:description><gtr:id>33ECCA9C-E444-45BB-A699-544961B28E54</gtr:id><gtr:impact>paper in preparation</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>David Lyons (Edinburgh) using zebrafish to examine molecular mechanisms of myelination, 2009, paper in preparation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CNR, University of Edinburgh-Shared PhD student on the &amp;quot;MS zebrafish&amp;quot;, funded by the CCBS.</gtr:description><gtr:id>82FAB680-54B7-41C4-9296-C4D54251C3EC</gtr:id><gtr:impact>NK</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Shared PhD student on the &amp;quot;MS zebrafish&amp;quot;, funded by the CCBS.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Wyeth Pharmaceuticals</gtr:department><gtr:description>TMRI/Wyeth - completion of translational studies of biomarkers of muscle loss, large cohort study for molecular and proteomic biomarker identification in muscle loss and regeneration (sarcopenia &amp;amp; cancer cachexia),</gtr:description><gtr:id>2E136B2A-003C-4E60-BAD2-C85417E987C9</gtr:id><gtr:impact>Publications in progress</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>completion of translational studies of biomarkers of muscle loss, large cohort study for molecular and proteomic biomarker identification in muscle loss and regeneration (sarcopenia &amp;amp; cancer cachexia),</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Stem Cell Technologies</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Stem Cell Technologies-George White</gtr:description><gtr:id>5EF6E730-1A09-430A-85CA-910A0D8F4389</gtr:id><gtr:impact>Work in progress</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>George White</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Peter MacCallum Cancer Centre</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Melbourne-analysis of Scribble function in meylination,</gtr:description><gtr:id>3E31E5E3-1D87-4CB6-BE6F-8ADE3B715D36</gtr:id><gtr:impact>Work ongoing</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Patrick Humbert (Melbourne) analysis of Scribble function in meylination, work ongoing</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>University of Liverpool-Kevin Park</gtr:description><gtr:id>19CF0C7A-E784-47C2-953C-F5927D57BAEA</gtr:id><gtr:impact>Work in progress</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Kevin Park</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>University of Edinburgh-analysis of the stem cell response in animal models of schizophrenia and bipolar disorder,</gtr:description><gtr:id>FD59D317-A03F-41FC-85E8-9FB7957D7515</gtr:id><gtr:impact>paper submitted to Molecular Psychiatry</gtr:impact><gtr:partnerContribution>Research results</gtr:partnerContribution><gtr:piContribution>Andrew McIntosh and David Porteus (Edinburgh), analysis of the stem cell response in animal models of schizophrenia and bipolar disorder, 2009</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Multiple Sclerosis Society</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>National Multiple Sclerosis Society funded translational research project funded under Promise 2010 initiative.</gtr:description><gtr:id>E4910A95-846B-46EA-9E90-01CDC9CD8409</gtr:id><gtr:impact>2 papers in 2009 - JCB, J Neurosci.</gtr:impact><gtr:partnerContribution>National Multiple Sclerosis Society funded translational research project funded under Promise 2010 initiative. Lead PI responsible for project coordination and identification of new targets for remyelination.</gtr:partnerContribution><gtr:piContribution>National Multiple Sclerosis Society funded translational research project funded under Promise 2010 initiative. With Franklin (Cambridge), Baron (Paris), Martino (Milan), Rowitch (UCSF), Goldman (Rochester), Antel (Montreal), Weiss (Calgary). Lead PI responsible for project coordination and identification of new targets for remyelination.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>University of Edinburgh-Analysis of the perdurance of the pluripotent state in vivo and in vitro.</gtr:description><gtr:id>6442C10B-D996-4F14-A202-2BBFB32427B9</gtr:id><gtr:impact>Tsakiridis, A., Tzouanacou, E.,Rahman, A., Colby, D., Axton, R., Chambers, I., Wilson, V., Forrester, L. and Brickman, J. (2009) Expression-independent gene trap vectors for random and targeted mutagenesis in embryonic stem cells. Nucleic Acids Res. 37, e129. &amp;amp; Osorno, R., Tsakiridis, A., Cambray, N., Economou, C., Wymeersch, F., Wilkie, R., Scotting, P., Chambers, I. and Wilson, V. The developmental extinction of pluripotency is reversed by ectopic Oct4 expression. In preparation for re-submission to Nature. I.C. &amp;amp; V.W. are joint senior authors.</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Analysis of the perdurance of the pluripotent state in vivo and in vitro. Supported by funding from WT and CONACYT (I.C.) and MRC (V.W.).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of South Australia</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Ian Wark Institute</gtr:department><gtr:description>Ian Wark institute, Adelaide, Australia-Assessing nanoparticles cytotoxicity on stem cells with impedance sensing.</gtr:description><gtr:id>512B5874-755A-4E81-9188-BE11F5456A43</gtr:id><gtr:impact>Work presented at Biosensors 2010, Glagow. Manuscript in preparation.</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Ongoing: Assessing nanoparticles cytotoxicity on stem cells with impedance sensing.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Multicell Technologies</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Multicell Technologies-Maertin Schroeder</gtr:description><gtr:id>176C1A84-0019-471F-A903-F95806ED8596</gtr:id><gtr:impact>Work in progress</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Maertin Schroeder</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Stanford University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Stanford-Using destabilising domain fusions to probe protein function in pluripotent cells.</gtr:description><gtr:id>A651D3D3-B839-4F19-88A2-93E3D88370BA</gtr:id><gtr:impact>Grant funded; 2010-2013 HFSP Programme grant (IC, lead PI) &amp;quot;A microfluidic, small molecule approach to perturbation of the pluripotency transcription network.&amp;quot; I.Chambers, T.Schroeder, T.Wandless &amp;amp; L.Lee. $1,200,000 US</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Using destabilising domain fusions to probe protein function in pluripotent cells. Supported by funding from WT &amp;amp; HFSP.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute for Research on the Spinal Cord and Brain (IRME)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>IRME, Paris, France -Catherine Lubetzki, IRME, Paris, France - started 2006.</gtr:description><gtr:id>3C404597-4235-4898-8A56-62568CB0DCD5</gtr:id><gtr:impact>Paper under review at the journal &amp;quot;Brain.&amp;quot;</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Catherine Lubetzki, IRME, Paris, France - started 2006.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pasteur Institute, Paris</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Jean-Fran&amp;Atilde;&amp;sect;ois Nicolas and Elena Tzouanacou&amp;nbsp;-clonal lineage analysis,</gtr:description><gtr:id>8E2CECF3-9DBA-48EB-A815-994690C77BF1</gtr:id><gtr:impact>paper in Dev Cell 2009.</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Collaboration with Jean-Francois Nicolas and Elena Tzouanacou on clonal lineage analysis, &amp;nbsp;&amp;nbsp;Funded by FPV network Eurostemcell and BBSRC</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC-Exocytosis in hepatocytes - Rory Duncan, Centre for Integrative Physiology, UoE</gtr:description><gtr:id>5E5025F7-6EE4-4A33-B336-6E3C9DF9E59D</gtr:id><gtr:impact>NK</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Exocytosis in hepatocytes - Rory Duncan, Centre for Integrative Physiology, UoE</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Life Technologies</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Life Technologies-Joydeep Guswami</gtr:description><gtr:id>7A659A59-54EB-47DA-8684-D4147B2134EB</gtr:id><gtr:impact>Work in progress</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Joydeep Guswami</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Stem Cell Research Edinburgh</gtr:department><gtr:description>CB Collaboration with ISCR Edinburgh</gtr:description><gtr:id>41812C71-5E6C-48DB-9D98-7EE1A25E4FA6</gtr:id><gtr:impact>NK</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>NK</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute for Research on the Spinal Cord and Brain (IRME)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>IRME, Paris, France-Paper accepted in Annals of Neurology.</gtr:description><gtr:id>7F28569A-DA7C-41D4-B78D-5A4F5E3887B2</gtr:id><gtr:impact>Paper accepted in Annals of Neurology.</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Paper accepted in Annals of Neurology.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Stem Cells for Safer Medicines (SC4SM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Generating models of hepatic endoderm from hESCs suitable for industrial application</gtr:description><gtr:id>F4C538B7-1A05-4236-9B25-3935B24F28E1</gtr:id><gtr:impact>Grant awarded 2009 &amp;pound;180k - Stem Cells for Safer Medicine</gtr:impact><gtr:partnerContribution>Collaboration in generating models of hepatic endoderm from hESCs suitable for industrial application</gtr:partnerContribution><gtr:piContribution>Collaboration with Josh Brickman in generating models of hepatic endoderm from hESCs suitable for industrial application</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>McGill University</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>Montreal Neurological Institute</gtr:department><gtr:description>Role of Runx1 in neural development</gtr:description><gtr:id>0AC41AD1-E1D5-4ED3-A673-203FE5AE1420</gtr:id><gtr:impact>Publication in prestigeous scientific magazine PNAS: N. Stifani et al. (2008) &amp;quot;Suppression of interneuron programs and maintenance of selected spinal motor neuron fates by the transcription factor AML1/Runx1. Proc Natl Acad Sci USA 105, No 17, 64516456</gtr:impact><gtr:partnerContribution>We learned about the role of Runx1 in neural development which may have parallels with haematopoietic development and performed complex genotyping of compound transgenic embryos</gtr:partnerContribution><gtr:piContribution>We provided our Runx1 reactivatable knockout mouse model to Prof. S. Stifani</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bristol-Myers Squibb</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>iPerian</gtr:department><gtr:description>iPerian-Mike Venuti</gtr:description><gtr:id>833345C1-3843-4B7A-964A-2D6F6A6513E9</gtr:id><gtr:impact>Work in progress</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Mike Venuti</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Psychiatry (IoP)</gtr:department><gtr:description>Use of iPS cells to study ALS</gtr:description><gtr:id>28CD4F94-09A1-4EE4-AB12-1C462B05BE2C</gtr:id><gtr:impact>Neural populations of different genotype for further detailed study</gtr:impact><gtr:partnerContribution>Tisse samples from patients and an understanding of the genetics of the disease</gtr:partnerContribution><gtr:piContribution>Derive iPS cells from patients with inherited cases of ALS along with age and geneder matched controls</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CCBS, University of Edinburgh -Second supervisor to PhD student, . Funding from CCBS.</gtr:description><gtr:id>027366B5-5115-41F4-BCEB-06E592EDD73C</gtr:id><gtr:impact>paper in &amp;quot;Multiple Sclerosis&amp;quot;</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Second supervisor to PhD student, . Funding from CCBS.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>YK Collaboration with Edinburgh</gtr:description><gtr:id>AAF4E946-C16A-463A-875D-F33C2923F074</gtr:id><gtr:impact>NK</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>NK</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Uppsala</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>AM Collaboration with Uppsala</gtr:description><gtr:id>5E737003-8C90-47A4-B600-B1A777B945C0</gtr:id><gtr:impact>NK</gtr:impact><gtr:piContribution>NK</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRc-iPS creation and stem cell differentiation via small molecules - Dave Adams, Heriot-Watt,&amp;nbsp;</gtr:description><gtr:id>0E2726D8-FF3B-407E-9AAB-D3F142CC86EB</gtr:id><gtr:impact>Prelimary work underway</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>iPS creation and stem cell differentiation via small molecules - Dave Adams, Heriot-Watt,&amp;nbsp;</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hull York Medical School</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CB Collaboration with Hull/York</gtr:description><gtr:id>113A6A93-8618-4FC4-8D85-D24618D0F4CF</gtr:id><gtr:impact>NK</gtr:impact><gtr:piContribution>NK</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Studying transplantation of hESC-derived hepatic endoderm into animal models</gtr:description><gtr:id>EE0BC84B-0049-46DB-9249-89FE67FE523F</gtr:id><gtr:impact>MRC Grant awarded (&amp;pound;500k)</gtr:impact><gtr:partnerContribution>Collaboration in studying transplantation of hESC-derived hepatic endoderm into animal models</gtr:partnerContribution><gtr:piContribution>Collaboration with Philip Newsome and David Adams in studying transplantation of hESC-derived hepatic endoderm into animal models</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Netherlands Academy of Arts and Sciences (KNAW)</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:department>Hubrecht Institute</gtr:department><gtr:description>Jacqueline Deschamps- Cdx2 and axial progenitors.</gtr:description><gtr:id>641462BF-854D-437E-A128-C966F9E33430</gtr:id><gtr:impact>paper in Dev Biol 2010.</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Collaboration with Jacqueline Deschamps on Cdx2 and axial progenitors.&amp;nbsp;&amp;nbsp;Started 2006, &amp;nbsp;&amp;nbsp;Funded by BBSRC and MRC.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC-MRC clinical training fellowship (2010) for Robert Drummond on pancreas development - P Shiels, University of Glasgow (co-supervisor), Kevin Docherty (collaborator), University of Aberdeen. [CRM liver grouping &amp;amp; external collaborators].</gtr:description><gtr:id>191F38DB-5367-4C05-8310-25C7F5D055A8</gtr:id><gtr:impact>NK</gtr:impact><gtr:partnerContribution>Research support</gtr:partnerContribution><gtr:piContribution>MRC clinical training fellowship (2010) for Robert Drummond on pancreas development - P Shiels, University of Glasgow (co-supervisor), Kevin Docherty (collaborator), University of Aberdeen. [CRM liver grouping &amp;amp; external collaborators].</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>University of Edinburgh-analysing cell adhesion molecules in myelination</gtr:description><gtr:id>23844DE4-E2A1-445E-8C53-C2F6BA2EE2D3</gtr:id><gtr:impact>NK</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Peter Brophy (Edinburgh), shared Wellcome Trust programme grant analysing cell adhesion molecules in myelination, 2008, work ongoing</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC funded A genetic approach to develop novel mouse models of liver disease</gtr:description><gtr:id>DEBB3768-71A0-4CEC-8652-0C279FF10463</gtr:id><gtr:impact>Mouse models will be made available to the community once validation is complete</gtr:impact><gtr:partnerContribution>Several mouse models of liver disease have been established and are now being validated</gtr:partnerContribution><gtr:piContribution>Characterisation of disease models</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Molecular Haematology Unit</gtr:department><gtr:description>AS Collaboration with MRC MHU</gtr:description><gtr:id>A33C23B5-9122-442B-9D8E-FC9378057A8F</gtr:id><gtr:impact>NK</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>NK</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Clinical Sciences Nottingham</gtr:department><gtr:description>Generating models of nutritional programming</gtr:description><gtr:id>0B14752D-9BDD-4D7D-A508-369C099B7BD9</gtr:id><gtr:impact>BBSRC grant awarded 2009 &amp;pound;1.3m</gtr:impact><gtr:partnerContribution>Collaboration in generating models of nutritional programming</gtr:partnerContribution><gtr:piContribution>Collaboration with Lorraine Young generating models of nutritional programming</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC-Heparan sulfate in human liver and pancreas development, Cathy Merry, University of Manchester, 2010</gtr:description><gtr:id>9B1C25E6-AFFF-425F-8797-1745D4B58759</gtr:id><gtr:impact>preliminary work underway</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Heparan sulfate in human liver and pancreas development, Cathy Merry, University of Manchester, 2010</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Development of AGM reaggregation system</gtr:description><gtr:id>FF1B771C-02CC-45D9-AFCC-445BC4A087C0</gtr:id><gtr:impact>Two publications in prestigeous Cell Stem Cell magazine and Genesis: 1. S. Taoudi et al. (2008) Extensive hematopoietic stem cell (HSC) generation in the AGM region via maturation of VEcadherin+ CD45+ predefinitive HSCs. Cell Stem Cell 3, 99108 2. J. Sheridan et al., &amp;quot;A novel method for the generation of reaggregated organotypic cultures that permits juxtaposition of defined cell populations&amp;quot; Genesis 47, 34651</gtr:impact><gtr:partnerContribution>Novel protocol for thymus reaggregation technique was provided to us which further refined by us resulted in development of a new powerful ex vivo HSC expansion analytical system</gtr:partnerContribution><gtr:piContribution>Developed a new powerful analytical system enabling generation of HSCs ex vivo</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Surrey</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Daphne Jackson Trust</gtr:department><gtr:description>Daphne Jackson Fellowship-Joanna Brzeszczynska (2010-2012) sponsored by the Leverhulme Trust. Role of miRNAs in muscle pathophysiology.</gtr:description><gtr:id>B8C12AF9-B3A6-4B98-88B0-870A1DC42B40</gtr:id><gtr:impact>NK</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Joanna Brzeszczynska (2010-2012) sponsored by the Leverhulme Trust. Role of miRNAs in muscle pathophysiology.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>University of Edinburgh-Structure-function investigations of Nanog and partner proteins</gtr:description><gtr:id>5899EB31-ADBC-408E-B510-29B0D7115CA5</gtr:id><gtr:impact>Papers: Mullin, N.P., Yates, A., Rowe, A., Nijmeijer, B. Barlow, P.N., Walkinshaw, M.D. and Chambers, I. (2008) The pluripotency rheostat Nanog functions as a dimer. Biochem. J. , 411, 227-231 Cited in Faculty of 1000: http://f1000biology.com/article/id/1137963/evaluation &amp;amp; van den Berg, D.L.C., Snoek, T., Mullin, N.P., Yates, A., Bezstarosti, K., Demmers, J. Chambers, I. and Poot, R.A. (2010) An Oct4-centred protein interaction network in embryonic stem cells. Cell Stem Cell, 6, 369-381. Grants funded; 2008-2011 Wellcome Trust Project 'Biochemical Interactions of the Pluripotency Rheostat, Nanog'. I. Chambers, (P.I.). M. Walkinshaw &amp;amp; P. Barlow, &amp;pound;267,873 &amp;amp; 2005-2007 BBSRC project 'Structure-function relationship of the novel ES cell transcriptional determinant Nanog'. I. Chambers, (P.I.), M. Walkinshaw &amp;amp; P. Barlow, &amp;pound;359,327.</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Begun 2005. Structure-function investigations of Nanog and partner proteins. Supported by funding from BBSRC &amp;amp; WT.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>McGill University</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>McGill, Montreal, Canada-Assessing stem cell viability in 3D scaffold with FDOCT.</gtr:description><gtr:id>DA97D129-EE75-4385-9429-F3E0852B10D1</gtr:id><gtr:impact>Work accepted for Photonics West, BIOS 2011, San Francisco, manuscript published in JBO (2011)
Work to be presented at FSB 2012. 
1st PhD visit: 2011
2nd PhD Visit from January to March 2012</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Ongoing: 6 Months Ph. D. student exchange, 2010 and 2011. Assessing stem cell viability in 3D scaffold with FDOCT.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>NIH funded Quantum project to develop artifical niches for stroke repair</gtr:description><gtr:id>7428FA16-D880-4AB6-91AD-2C6C2A22AF29</gtr:id><gtr:impact>Paper submitted to Stem Cells</gtr:impact><gtr:partnerContribution>Collaborated on NIH funded Quantum project to develop artifical niches for stroke repair. Co-PI responsible for Mapping CNS stem cell niche in normal adult and following injury</gtr:partnerContribution><gtr:piContribution>NIH funded Quantum project to develop artifical niches for stroke repair With Hirschi/Dickinson/Brenner/Rice (Baylor), Price/Modo (Kings), Lovell-Badge (NIMR) Co-PI responsible for Mapping CNS stem cell niche in normal adult and following injury</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>University of Edinburgh-Bioinformatic analysis of gene expression and chromatin binding in pluripotent cells.</gtr:description><gtr:id>03203EC2-9D10-499F-A4FD-FAA5F5EF7969</gtr:id><gtr:impact>Paper: Chambers, I. and Tomlinson, S. (2009) The transcriptional foundation of pluripotency. Development, 136, 2311-2322, Grant submitted; MRC programme grant application &amp;quot;Transcription factor dynamics in control of pluripotent cell function and identity&amp;quot; (I. Chambers, P.I.) submitted 01/09/10; decision due Feb 2012.</gtr:impact><gtr:partnerContribution>Researh output</gtr:partnerContribution><gtr:piContribution>Bioinformatic analysis of gene expression and chromatin binding in pluripotent cells. Supported by funding from WT and EuroSyStem.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Utrecht University</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Unviersity of Utrecht -Jan Schrickx</gtr:description><gtr:id>7CAA11C2-2651-40B1-B280-EDEE1BFCB0F7</gtr:id><gtr:impact>Work in progress</gtr:impact><gtr:partnerContribution>Research output</gtr:partnerContribution><gtr:piContribution>Jan Schrickx</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Visits / talks / written interviews for patient groups - 2009</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>7906E2CC-168B-4DF5-B755-E28A216C311C</gtr:id><gtr:impact>Various visits and talks to patient groups, including: - Dr Anna Williams hosted a stem cell workshop at MS Myspace conference for MS patients and their families in Perth. - Dr Anna Williams gave a lecture and Q&amp;amp;A meeting at Craighall MS Community Group. - Following a donation of &amp;pound;10k for the Kinross branch of the MS Society Dr Anna Williams hosted a visit of the group at the Centre. - Dr Tilo Kunath has had visits from various individual Parkinsons patients. - Dr Tilo Kunath hosted a visit at the Centre for the PD Society's branch Edinburgh Young Parkinson's. - Several interviews in (local) patient group magazines, including MS Society and PD Society.

dissemination and raising awareness at local community level as well as national level.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Development of teacher resources</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>96359B22-3543-4737-8B47-F9083A1B7590</gtr:id><gtr:impact>Development of teacher resources for secondary schools, worksheets on stem cells which can be downloaded from the EuroStemCell.org website. EuroStemCell comms manager Emma Kemp and CRM comms officer Ingrid Heersche involved.

Better equipped teachers (up to date content on stem cell research), to pass on to their secondary school students</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Stem Cell Roadshow</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>DFCAABF9-1E8D-4B9F-9CC9-28E9B5AF4573</gtr:id><gtr:impact>Set up of SSCN Stem Cell Roadshow to secondary school pupils in Scotland as well as delivery of one of the events. 4 schools, 100 pupils in total. Researcher Dave Hay involved.

Raising awareness of stem cell applications in the future, discussing ethical issues surrounding research.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visits</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>BE656EB2-5D39-424B-8E71-AC6011EA44F7</gtr:id><gtr:impact>Development of a stem cell lesson for use by educators as part of the EuroSyStem and EuroStemCell project. Piloted at 3 schools (368 students in total). Development done by of EuroSyStem / EuroStemCell outreach manager Emma Kemp with one CRM researcher Ian Chambers. To be finalised in 2011. Schools included Tynecastle High School (Edinburgh) and The Derby School (Lancashire)

Awareness and understanding of basic stem cell science &amp;amp; ethics</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TickTock Media Ltd student guide on stem cell research - Sept 09 - ongoing</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>45E3B9D6-A939-4D8F-B417-AD957D21B976</gtr:id><gtr:impact>TickTock MEDIA LTD, a publisher of educational materials, are producing a booklet for secondary school students on Stem Cell Technology. This will be published in 2010. Professor Sir Ian Wilmut has contributed a case study about his work. Various staff have contributed to the editing process.

Remains to be seen, will be published in 2010.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Exhibit 'Stem Cells for Blood Transfusion?'</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>4DDCE940-DEC5-4BA9-91F6-60F38A388C45</gtr:id><gtr:impact>Development and delivery of this exhibit together with Glasgow University and Irish and Scottish Blood Transfusion Service. Researchers Marc Turner &amp;amp; Lesley Forrester involved as well as CRM comms officer Ingrid Heersche. In addition 12 additional demonstrators (staff &amp;amp; students) for actual delivery at the event. 13,000 visitors to the exhibit (49,946 total visitors to festival).

Raising awareness of stem cell applications in the future, discussing ethical issues surrounding research.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Schools Tour September - September / October 2008</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>351651B6-7C55-4DD5-BCD7-275C1A7E9313</gtr:id><gtr:impact>The activity was organised together with The University of Edinburgh's SCI-Fun team. 8 local secondary schools were visited: ?Peebles HS (Scottish Borders) ?St George's School (Edin) ?Tynecastle HS (Edin) ?Newbattle CHS (Midlothian) ?Preston Lodge HS (East Lothian) ?Liberton HS (Edin) ?St Margaret's Ac (West Lothian) ?Queensferry HS (Edin) It was a morning or afternoon programme for the whole year group (S1 or S2, school decided) that consisted of: -two presentations (a stem cell show and a senses show) -a hands-on exhibit -a career show -a meet-the-scientist session (of the Centre) Total number of S1 / S2 students 1136 Total number of senior students 245 Total number of teachers 60

Engaged schools in the research that goes on at the Centre.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visits / talks / written interviews for patient groups</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>3B5599DF-A46F-4750-863A-DE7E9436910A</gtr:id><gtr:impact>Several lectures to patient groups by several researchers, total number of patients involved approx 100 (MS branches in Perth and Irvine; Leukaemia and Lymphoma Research Scotland, Parkinson's UK). Researchers Charles ffrench-Constant, Anna Williams, Tilo Kunath and Clare Blackburn involved.

Better informed patients &amp;amp; relatives about advances and future of regenerative medicine</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public lecture - Mexico</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>73404490-3103-4A4E-B549-844B10D77F87</gtr:id><gtr:impact>Public lecture on stem cell banking to mark opening of stem cell facility, Guadalajara , Mexico. Physicians, members of the public. CRM researcher Josh Brickman involved.

Awareness and understanding of basic stem cell science &amp;amp; ethics</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Chair of organising committee</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>5FDE06DB-2AE6-4367-81C6-0A1E1E97CC7E</gtr:id><gtr:impact>Neurology Symposium at the Royal College of Physicians, Edinburgh, October 2010 - chair of organising committee. Audience - general physicians, neurologists and students from the UK. CRM Researcher Anna Williams involved.

Better informed health professionals about advances and future of regenerative medicine.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CRM Media activity - 2008</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>8C7E8DAD-CD4F-400D-AED2-581FD2A38E5F</gtr:id><gtr:impact>Various press releases &amp;amp; expert comments. Exposure in local, regional, national and international newspapers as well as TV (BBC news). Most important ones: - PubMed 18593562, Prof Alexander Medvinsky reports on a paper published in cell stem cell (July 08). - PubMed 18802003, Dr Ian Chambers reports on a paper published in Science (Nov 08). - Opening of the Centre (Nov 08). - Appointment of Dr Siddharthan Chandran (Nov 08). - MRC / UK Stem Cell Foundation / Scottish Enterprise &amp;pound;3.6M grant to find ways to repair bone &amp;amp; cartilage. Prof Brendon Noble (May 08). - Launch of Prof Charles ffrench-Constant's MS Centre with donation of JK Rowling (Apr 08), Emphasis on importance of research on MS by JK Rowling (July 08, newspapers as well as documentary on BBC 1 Scotland) - Schools Stem Cell Tour (Oct 08)

national exposure to the general public about the work done at the centre as well as showing the importance of research on stem cell &amp;amp; regenerative medicine.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at Scottish Stem Cell Network</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>14473AC1-3C62-4E48-8BAD-AB3A98C7BFCE</gtr:id><gtr:impact>Public debate on the ethics of the use of embryonic stem cells

Part of a general objective of disseminating infomration concerning regenerative medicine</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CRM Media activity - 2009</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>1AB3FFA2-29AB-44E1-9E03-3C71656A2B4B</gtr:id><gtr:impact>Various press releases &amp;amp; expert comments. Exposure in local, regional, national and international newspapers as well as BBC TV. Most important ones: - PubMed 19252477 and 19252478. Dr Keisuke Kaji explains about his work published in two Nature papers (March 09). - PubMed 19877180. Dr Gareth Sullivan and Prof Sir Ian Wilmut explain about the work published in Hepatology (October 09). - Collaboration between Scotland/UK and China on stem cell research and regenerative medicine (April 09). - Opening of the Euan MacDonald Centre, Prof Siddharthan Chandran (August 09). - &amp;pound;2.9M funding by Wellcome Trust for Prof Marc Turner on using stem cells to generate red blood cells for use in transfusions (Apr 09). - &amp;pound;0.4M funding by PD Society for Dr Tilo Kunath.

National exposure to the general public about the work done at the centre as well as showing the importance of research on stem cell &amp;amp; regenerative medicine.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Family Day - 23 November 2008</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>D3D7AD7B-97FE-4CA1-B4BF-4EF1D47D8AD3</gtr:id><gtr:impact>Approximately 500 people attended this event. Many of our scientists of the Centre were involved. We hosted a free Stem Cells Family Day event at Our Dynamic Earth (ODE) in Edinburgh, as a prelude to our Launch Symposium the day after. An introduction to some of the current work being undertaken in stem cell research. Events and exhibits included the following: ? stem cell and life science hands-on exhibits and presentations; ? a &amp;quot;meet the scientist&amp;quot; session; ? the announcement of the winners of the Stem Cell school poster competition, and the display of all of the finalists' posters; ? screening of the award-winning 19 minute film, &amp;quot;A Stem Cell Story&amp;quot;; ? a mini-lab, giving visitors a chance to try out some of their laboratory skills, with the following tasks: o using an ultrasound scanner to identify the contents of pre-loaded boxes (a variety of shapes and figures were embedded in opaque gel); o a microscope and flasks of stem cells - embryoid bodies, cardiomyocytes and undifferentiated stem cells - giving the lab &amp;quot;assistants&amp;quot; an opportunity to see stem cells &amp;quot;in the flesh&amp;quot;; o a simulated drug screening exercise (adding weak acid to phenol red solution, which changed colour); o loading agarose gel wells with coloured dye using real lab pipettes: this was a representation of how DNA and RNA are actually analysed in the lab.

We raised awareness in the local community of Edinburgh for stem cell research and regenerative medicine in general as well for the opening of the Centre.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Activity 'Making PlayDoh Stem Cells'</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>A62844B5-6D41-4E30-A7D3-DA46019E6D97</gtr:id><gtr:impact>Activity part of the MRC Lab 'What are scientists made of, the same as you'. One of 6 stalls on making PlayDoh cells from stem cells. 15 days, total children participated in one or more activities 1,300 (MRC statistics). Organised by MRC, small contribution to development of Stem Cell activity by CRM comms officer Ingrid Heersche. Three CRM staff/studensts helped out as demonstrators at the event.

Part of a general objective of disseminating infomration concerning regenerative medicine</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Various press releases &amp; expert comments</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>C39DAB5A-9165-49F6-AE09-E2F33487031B</gtr:id><gtr:impact>Various press releases &amp;amp; expert comments with exposure in local, regional, national and international newspapers as well as TV (STV news).

Part of a general objective of disseminating infomration concerning regenerative medicine</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>X-mas lecture at University of Edinburgh - 04 December 2009</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>F9872B32-9D95-4E4A-BCD9-4D0C9627A061</gtr:id><gtr:impact>Prof Charles ffrench-Constant and Prof Siddharthan Chandran on 'Stem Cells for Neurological Disorders - where now' (Dec 09). Approx 300 people attended this lecture, which was followed by a short Q&amp;amp;A session and a drink. Available online: http://www.edinburghneuroscience.ed.ac.uk/christmaslecture/2009/

More knowledge on stem cell research in general as well as exposure for all the Centres involved (CRM, MS Centre, Euan MacDonald Centre).</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Contribution to the redevelopment of a 16+ student BBSRC booklet 'Stem Cells Science &amp; Ethics'</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>1A9B4C55-0C37-40EE-890E-CE25C6D18375</gtr:id><gtr:impact>Contribution to the redevelopment of a 16+ student BBSRC booklet 'Stem Cells Science &amp;amp; Ethics'. Case studies from CRM researchers Anna Williams, Keisuke Kaji, Lesley Forrester. Science chapter written by CRM PostDoc Nina Bauer, edited by CRM researcher Clare Blackburn and Comms officer Ingrid Heersche. Pictures also provided.

Better understanding of basic stem cell science and ethics by 16+ secondary school students.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture to Scottish MS Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>B04AEBDC-B968-41E7-A383-CC050D7F3DAE</gtr:id><gtr:impact>Invited lecture to Scottish MS conference Perth 2010. Overview of MS and ongoing research, health professionals and patients

Part of a general objective of disseminating infomration concerning regenerative medicine</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Four Inagural Lectures</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>EF2588B9-FFC7-4764-BBF4-7A7D01D6A72D</gtr:id><gtr:impact>Four one hour lectures by Prof Charles ffrench-Constant, Prof Jim Ross, Prof Siddharthan Chandran and Prof Marc Turner

Dissemination and raising awareness at local community level on stem cells &amp;amp; regenerative medicine</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Response to patient enquiries - 2010</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>6A8CE54A-96DE-48FA-9417-305ACA1630C9</gtr:id><gtr:impact>CRM receives approximately 60 - 80 patient enquiries per year that are always dealt with on an individual basis due to the sensitive and specific nature of these enquiries; we also answer approx 20 student queries per year. CRM comms officer Ingrid Heersche involved.

Better informed patients &amp;amp; relatives about advances and future of regenerative medicine.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Response to patient enquiries - 2009</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>E1955C66-9486-40B2-BD41-0B27955AE511</gtr:id><gtr:impact>The Centre receives approximately 60 - 80 patient enquiries per year. Patients are looking general information on stem cell research, information about stem cell trials and clinics, and medical advice about their treatment. Due to the sensitive and specific nature of these enquiries, they are always dealt with on an individual basis by the Centre's scientific communication officer or, occasionally, by the Centre's researchers.

More knowledge on stem cell research in general. The Centre has adopted a policy not to give advice regarding a specific stem cell treatment or clinical trial.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture to Christians in Science</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>560DA250-9377-48C6-AD96-B2470AE4A9A4</gtr:id><gtr:impact>Lecture to Christians in Sceince on stem cells 2009. Primary audience, Christians interested in science. CRM researcher Val Wilson involved.

Awareness and understanding of basic stem cell science &amp;amp; ethics</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Contribution to hard print booklet</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>084E332A-863C-4036-A5B3-CB251B14F8F6</gtr:id><gtr:impact>Contribution to the joint Institute of Physics and EPSRC report, &amp;quot;Optics and photonics: Physics enhancing our lives&amp;quot; available as a hard print booklet and on the web http://www.iop.org/publications/iop/2009/page_38205.html. CRM researcher Pierre Bagnaninchi involved.

Book publication</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.iop.org/publications/iop/2009/page_38205.html</gtr:url><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Edinburgh University Stem Cell Science Course - April to June 2009</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>C28815C8-C169-4938-A270-16E8D3C07521</gtr:id><gtr:impact>10 week evening course on Stem Cell Science organised by Dr Clare Blackburn, Dr Sally Lowell and Dr Tilo Kunath. Classes included lectures, discussions and seeing stem cells in the laboratory. Ten other Centre researchers (all PIs) were involved and gave lectures. There were 11 students enrolled in 2008/9. We may run this course again in 2010/11.

More knowledge on stem cell research in general as well as knowledge about the research done at the Centre.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School Stem Cell Poster Competition - November 2008</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>CF2A3DE4-EA91-475D-95E8-32ED316798FD</gtr:id><gtr:impact>The Stem Cell Poster Competition 2008 3 schools entered the poster competition. 2 teams from each school (S2 and senior) entered a poster. The work of the finalists and winners of was on display at the Family Day, the Launch Symposium and the Royal Society of Edinburgh's discussion forum: &amp;quot;Regenerative Medicine: how will it change my life?&amp;quot; Each S2 and senior team consisted of between two and four students, with a supervising teacher. The teams provided content and initial artwork, while the graphics and printing facilities of the University were used to realise the final posters.

Engaged awareness in schools about Stem Cell Research that goes on at the Centre.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Edinburgh neuroscience Christmas lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>C5032BBA-3D6C-49CF-93EA-F432885EEE9C</gtr:id><gtr:impact>Edinburgh neuroscience Christmas lecture, public and interested staff, overview of regenerative medicine and stem cells December 2009. CRM researchers Charles ffrench-Constant and Siddharthan Chandran involved.

Awareness and understanding of degenerative diseases &amp;amp; regenerative medicine</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public meeting at a church</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>75067140-99C8-4E86-BE1B-5E48C6FBC144</gtr:id><gtr:impact>Public meeting at a church for 50 people, including showing the films 'A Stem Cell Story' and 'Ethics, Science and Stem Cells' as well as a lively discussion. EuroStemCell comms manager Emma Kemp and CRM researcher Clare Blackburn involved.

Part of a general objective of disseminating infomration concerning regenerative medicine</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Centre visits</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>1418214A-F530-412F-8457-4A1C24A8053B</gtr:id><gtr:impact>12 secondary school teachers for a lab-tour, documentary films and lectures. EuroStemCell comms manager Emma Kemp and researchers Tilo Kunath and Ian Chambers involved for the day.

Better equipped teachers (up to date content on stem cell research), to pass on to their secondary school students</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EuroStemCell project 2010-2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>92CD29C8-448A-4C9D-82A8-79A1993D2D18</gtr:id><gtr:impact>Start of the 2nd EuroStemCell project 2010-2014, a large European consortium of researchers that reach out to the general public via a portal website www.eurostemcell.org, public engagement component is coordinated by CRM researcher Clare Blackburn. Outreach manager Emma Kemp and Webmanager Kate Doherty are also hosted within CRM, ongoing. The eurostemcell.org website had over 95,000 unique visitors in 2009. Development of teacher resources, films &amp;amp; patient information, to be translated in 9 European languages.

Awareness and understanding of stem cell research &amp;amp; regenerative medicine.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.eurostemcell.org</gtr:url><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Workshop on stem cells &amp; resources</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>1849E098-AA27-40AF-9326-77C31BAF445D</gtr:id><gtr:impact>Workshop on stem cells &amp;amp; resources for secondary school teachers as part of the annual ASE conference, 16 participants. EuroStemCell comms manager Emma Kemp and CRM comms officer Ingrid Heersche involved.

Better equipped teachers (up to date content on stem cell research), to pass on to their secondary school students</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public lecture - Sofia</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>F8595BAF-3F52-4774-B2D3-E79077698DC2</gtr:id><gtr:impact>Public lecture in Sofia, Bulgaria, [November 2009] as part of ESTOOLS 'Telescope' programme (for education of EU secondary students). CRM researcher Andrew Smith involved.

Awareness and understanding of basic stem cell science &amp;amp; ethics</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Launch Day - 24 November 2008</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>14843FA7-AF47-40A8-BC8C-456FE6A21F88</gtr:id><gtr:impact>The day was organised at Our Dynamic Earth in Edinburgh. 300 invited guests from all over the world; scientific community as well as politicians and members of the MRC. The day started at 8.30am and finished at 8.00pm. After a welcome reception, the day kicked off with four scientific sessions led by our scientists Ian Wilmut, Claus Nerlov, Marc Turner, and Charles ffrench-Constant. All our PIs presented their work in a poster session, some also in separate presentations. The official launch of the Centre happened at lunchtime, the day ended with an informal networking event during a wine and canap&amp;eacute; reception.

Raising the Centre profile in the international scientific community, the life sciences sector in Scotland as well as amongst the key politicians and policy makers in Scotland.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visits for students and secondary school children - 2009</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>776BB553-1FAC-4D55-B9B5-10523094DE49</gtr:id><gtr:impact>Various activities, including: - An afternoon programme for 20 American exchange students, involving two lectures by Prof Sir Ian Wilmut and Prof Stuart Forbes as well as a lab tour (Oct 09). - A visit from 3 secondary school students from a local school. Hosted by Dr Tilo Kunath and Dr Keisuke Kaji.

More knowledge on stem cell research in general, encouraging future scientists to work in the area of regenerative medicine, exposure for the Centre.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit - 16/17 November 2009</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>013CEADC-24FD-4088-8F6A-6784B040AE46</gtr:id><gtr:impact>Two day workshop at a local school (Liberton High School), involving 60 kids and 3 teachers (as part of a collaborative European project). Six Centre students and staff involved, including Dr Tilo Kunath. Part of the workshop was exchanging ideas with another European school.

More knowledge on stem cell research in general, encouraging future scientists to work in the area of regenerative medicine, exposure for the Centre.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visits / talks/ written inteviews for patient groups - 2008</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>C75DB44A-86A0-4AB0-8531-C1FAC71CD803</gtr:id><gtr:impact>Various visits and talks to patient groups, including: - MS Life lecture 2008 (Glasgow) - a meeting of the MS Society for patients and families - Hosted a visit by our principal donor JK Rowling.

dissemination and raising awareness at local community level as well as national level.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture in University &quot;Changing World&quot; series</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>9D50C5BE-B77E-465C-B617-0743A405FE46</gtr:id><gtr:impact>Public lecture 'The Future of Regenerative Medicine' as part of the Unversity's &amp;quot;Our Changing World&amp;quot; series. Public: general audience, students and schoolchildren, 9 November 2010, CRM researchers Charles ffrench-Constant &amp;amp; Siddharthan Chandran. 120 (?) attendees.

Awareness and understanding of degenerative diseases &amp;amp; regenerative medicine</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBSRC student guide on stem cell research - May 09 - ongoing</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>91B1885E-F882-41D5-AD79-4308867EBB9A</gtr:id><gtr:impact>BBSRC is updating a booklet for secondary school students. This will be published in 2010. Scientists of the Centre (Dr Anna Williams, Dr Lesley Forrester and Dr Keisuke Kaji) have contributed a case study about their work. Post Doc Dr Nina Bauer has written part of the scientific content. Various staff have contributed to the editing process.

Remains to be seen, will be published in 2010 by the BBSRC.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ISSCR public symposium - 07 July 2009</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>25D1249F-1F08-4367-9243-638453BE26D6</gtr:id><gtr:impact>Approximately 150 people attended the ISSCR Public Symposium, organised at the CosmoCaixa science museum in Barcelona. The event included: - A 'Smile of a Stem Cell' photographic exhibition - Two short films: the award-winning film 'A Stem Cell Story' and a first-ever viewing of a soon-to-be-released film on iPS cells. - an audience-panel discussion with a group of stem cell scientists. It was co-organised by EuroSyStem, Dr Clare Blackburn and Ms Emma Kemp of the Centre were involved.

More knowledge and awareness for stem cell research.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Edinburgh International Science Festival - April 2008</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>96B0711D-39DF-4DD4-8FD3-7C952C14DDCC</gtr:id><gtr:impact>Dr Keisuke Kaji explained about his recently published work in Nature at the well established Science Festival in Edinburgh. He gave a presentation and participated in workshops.

Information dissemination and raising awareness.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to Church group</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>3E0FF332-9E22-42EC-93D2-2B5C7DF94867</gtr:id><gtr:impact>Description of potential uses of stem cells to derive new treatments and discussion with audience

No specific outcomes</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public lecture / event</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>4D245571-D64F-4406-A9EA-E36105C951DA</gtr:id><gtr:impact>Part of the Big Ideas Programme. 'A Stem Cell Dream: can iPS technology be used to treat Parkinson's Disease'. Evening event where public had to vote if fictional trial had to go ahead or not. CRM researchers Tilo Kunath, Ian Wilmut and Siddharthan Chandran involved. Organised by Ingrid Heersche, chaired by BBC journalist Eleanor Bradford. 91 attendees, 14 April 2010.

Part of a general objective of disseminating infomration concerning regenerative medicine</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>51500</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MS Hope For A Cure-Autologous cell therapy - a neuroprotective strategy for MS/MS Hope for a Cure</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>MS Hope for a Cure</gtr:fundingOrg><gtr:id>857F92B1-0EF2-4E4F-A148-D7198C616A1C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>370000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Parkinson's Disease UK-Generation of induced pluripotent stem cells from people with Parkinson's disease.</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Parkinson's UK (Parkinson's Disease Society)</gtr:fundingOrg><gtr:id>BB7D64D2-6382-4FEF-A707-FB0E013EAA8C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>275000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cancer Research UK-Function of the C/EBP&amp;acirc;-CyclinD1 complex in epithelial cancers</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>77ECDA1D-DE67-40A1-A9B4-DBFC13DDF96C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>WT Studentship</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>390DAA37-1610-4EB9-88E0-BB3FB916FF87</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust-Vacation Scholarship for Susanne Maxwell:</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>E959C5F5-668F-43EB-BD4C-A4FFA0C2FE4E</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Biotechnology and Biological Sciences Research Council (BBSRC)-Steroid Receptors and transcriptional control of thymic rebound</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>D133565A-BA36-4FD4-9024-D00D6A0DFD13</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>49000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Multiple Sclerosis Society-Autologous adult human mesenchymal stem cells: a neuroprotective therapy for MS - supplement</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>Multiple Sclerosis Society</gtr:fundingOrg><gtr:id>9080DC70-1FC0-487D-BBB6-BBCD714765D3</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>130000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Engineering and Physical Sciences Research Council (EPSRC)-Bio-Active Polymer Driven Cell Based Systems - Predicting Human Drug Toxicity</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/H029680/1</gtr:fundingRef><gtr:id>EA4E80B8-5E42-4B25-B696-25BB77E36970</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>JDRF Pilot Project</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Juvenile Diabetes Research Foundation (JDRF)</gtr:fundingOrg><gtr:id>EAA6EC97-5FE6-4B97-81EE-61B27ABBC9CC</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1350000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leukaemia Research (Directing differentiation of Mouse and human embryonic stem cells into haematopoietic stem cells (HSC) using engineered embryonic HSC niches)</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>7F44564D-EB26-467F-A6A8-A68567BDADA4</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>LRF Project Grant</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>8E02A36B-4B7F-4C17-89CB-1749DEA93E46</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2400</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Foreign &amp;amp; Commonwealth Office-UK-US Stem Cell Collaboration Award/Foreign &amp;amp; Commonwealth Office</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Foreign and Commonwealth Office (FCO)</gtr:fundingOrg><gtr:id>7E8F9F96-1280-4D5A-90C5-080F5CB135DF</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EU Consortium for Stem Cell Biology</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>77AD16D8-9001-4B14-8E2B-EAC91365A225</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC iPS supplemental award</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>9D8CDB12-209D-44A9-8051-125FC1CF1965</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Role fo AML1/Runx1 isoforms in development</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>607A568C-80E8-4B58-89BC-45F704A47D65</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>140000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>European Commission/Marie Curie - Intra-European Fellowship-GRNES: Analysis of the gene regulatory network controlling ES cell identity/European Commission/Marie Curie - Intra-European Fellowship</gtr:description><gtr:fundingOrg>Marie Curie Actions</gtr:fundingOrg><gtr:id>5E52FE72-5FC8-4AF3-B441-706FDE3738AE</gtr:id><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>72000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of Cambridge-Transfer of Funds - David Hampton/University of Cambridge</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>University of Cambridge</gtr:fundingOrg><gtr:id>27171F50-E8EB-4B75-9EB6-CDA56D200912</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Scottish Biomedical Research Trust-Studentship in Biomedical Research/Scottish Biomedical Turst</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>SB Drug Discovery</gtr:fundingOrg><gtr:id>B109C81C-D21D-4103-BD8B-BD2BB1658FC4</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>16000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust-ECAT - Support for Piloting Virtual and Face to face Catalysts to Enthuse, Recruit and Retain the Most Able Clinical Academic Trainees</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>EBCE2262-EF57-4BD5-9BD2-1D34FF3470D3</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>LRF Senior Fellowship</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>5EBE0AC9-1CA1-4BF8-8196-64E6CA7A9E17</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>13000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ALLOSTEM: The Development of Immunotherapeutic Strategies to Treat Haematological and Neoplastic diseases on the Baiss of Optimised Allogeneic Stem Cell Transplantation (8m euros across 29 participants)</gtr:description><gtr:end>2008-03-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>52D56ED2-F7B6-4E56-B4BD-B9D90282D135</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2004-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>31500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Parkinson's Disease UK-Role of FGF signalling in maintenance and differentiation of human pluripotent cells.</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Parkinson's UK (Parkinson's Disease Society)</gtr:fundingOrg><gtr:id>30D1F0BB-E7CC-4183-9EAB-07C1BB7FB96F</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Stem Cell Sciences UK Ltd</gtr:department><gtr:description>CASE Studentship (Stem Cell Sciences)/stem cell sciences</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Babraham Institute</gtr:fundingOrg><gtr:id>4F60C319-A725-4BB7-A5C9-39766CE951CC</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>230000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust-ECAT: Sokhi: Developmental Genetics Analysis of Post-Axial Transverse Limb Reduction deformity (PATLRD) (FitzPatrick, MRC HGU)</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>AFE67A28-105C-485E-9022-7F3E6CDFF56A</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Motor Neurone Disease Association-Modelling motor neuron disease using induced pluripotential stem cells.</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:id>B5293B0E-B49C-4AD1-8B14-552B77BEA5ED</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>427826</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ESTOOLS (12m euros across 23 participants)</gtr:description><gtr:end>2010-07-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>04E9CCEE-965B-484B-9F6A-62EA55298B79</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2006-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Ontogeny of haematopoietic stem cells</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>921D5DD5-98BC-4C74-846A-3CA5854E805E</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>650000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BEST-Stem Cells: Bio-chemically Equivalent Substitutive Technology for Stem Cells (RTD-budget CMVM)</gtr:description><gtr:end>2012-06-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>C9045A30-3113-490E-8020-1D498F6A56FF</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EU Consortium for Stem Cell Biology/EU Consortium</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>D21BB301-5E6D-42DB-975C-4302060674DB</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>290000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Research Council (MRC)-Clinical Training Fellowship for Mike Williams: Defining the functional role of the progenitor cell-laminin interaction during liver regeneration</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>0D71EBE6-1925-4D01-8770-1AC2BB5C5A61</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1100000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Optistem - Optimization of Stem Cell therapy for clinical trials degenerative skin and muscle disease (12m euros across 18 participants)</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>37D6DBAE-5CAE-4E91-AD12-D9E6AB11553D</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC funding (Generating models of nurtitional programming)</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>8C538BBB-DE80-4117-8C03-20DB78ED7356</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIH Program Project Grant PO1/NIH</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>E0CCEC6F-1B10-406B-9F77-42C56465EDFB</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>61890</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EUROSTEMCELL-European consortium for communication of stem cell research/eurostemcell (0.8m euros across 11 participants)</gtr:description><gtr:end>2014-02-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>0B1C16B6-4911-4AE4-A0BB-A5E421BB0CF7</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2010-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC funding (Screening polymer libraries using hESC-derived hepatic endoderm)</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>77FF0C10-BD56-4863-B7FD-0E9AF1CF39A8</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>190000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leukaemia Research Foundation-In vitro propagation of mouse and human fetal thymic epithelial progenitor cells/Leukaemia Research Foundation</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>EB2ACA83-A5A1-46BB-982C-A139D87874AE</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>240000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust-ECAT: Aldridge: The Role of CDK11 - Mediated Autophagy in Tumour Cells and the Impact of Dysregulation on Tumourgenesis (Frame)</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>CD05B63E-A6DE-4AD5-AF16-1AD7BE0CE7FE</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>JDRF Pilot Project</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Juvenile Diabetes Research Foundation (JDRF)</gtr:fundingOrg><gtr:id>1CE7EC44-3709-48EE-ABBE-15066F55BA00</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>WT Studentship</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>4ED56F18-D9E4-4C0F-813E-AAF492ABF22E</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>870000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Research Council (MRC)-Development of a non-invasive strategy enhancing haematopoietic stem cell (HSC) potential of human umbilical cord cells</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>D550F212-CAC9-4497-8D02-1E4296B45392</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>199000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Scottish Motor Neurone Disease Association-Scottish MND register - a prospective and collaborative platform for improved care, prognostic modelling, research and clinical trials./Scottish Motor Neurone Disease Association</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>MND Scotland</gtr:fundingOrg><gtr:id>8560A27C-8EF2-4695-8C06-05778FD88118</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1400</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust-Vacation Scholarship for Jayanthi Sethunarayanan: of &amp;acirc;-globin expression in HoxB4 overexpressed muring and human embryonic stem</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>EA5D3AFF-E04F-437D-8521-1DDFE5B71AF8</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>225000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust-ECAT: Lucas: Modulation of Inflammatory Cell Apoptosis in Infectious Lung Injury (Rossi)</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>3EC19F64-B32C-4692-AB79-6ECBE86CB09D</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>Australia, Commonwealth of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>National Health and Medical Research Council (Australia)</gtr:department><gtr:description>AHMRC CJ Martin Fellowship /AHMRC</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Australian Government</gtr:fundingOrg><gtr:id>98EA9DD7-DD26-4F1D-A013-1271BC7FB916</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Sir Jules Thorn Trust Award (&amp;pound;1.1M National reseach competition), 2007</gtr:description><gtr:end>2010-04-02</gtr:end><gtr:fundingOrg>Sir Jules Thorn Charitable Trust</gtr:fundingOrg><gtr:id>EEDB8FFD-4929-401F-8324-ED708AB68E77</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>RCUK Fellowship</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Research Councils UK (RCUK)</gtr:fundingOrg><gtr:id>A449A7FE-B59C-43C3-A3D2-02CDC842C609</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>330000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Research Council (MRC)-Development of Retinal Transplantation as an Animal Model to Test Stem Cell Therapies for Myelin Diseases</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>C237CB6F-C7B9-478D-8D39-8C92C12E7B80</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>650000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Research Council (MRC)-Characterisation and culture of neuromesodermal stem cells</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>D4FEC3F7-C981-4F0C-AEC5-D563F3736F8D</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>400</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Scottish Biomedical Research Trust-Studentship in Biomedical Research/Scottish Biomedical Research Trust</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>SB Drug Discovery</gtr:fundingOrg><gtr:id>EFB04E92-2056-4689-9AD0-460AA7A34D89</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2010-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Research Grant (Studying transplantation of hESC-derived hepatic endoderm into animal models)</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>59162CFC-F5FB-48BF-87B8-686E5479CFBA</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>WT VIP award</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>C11A094C-EBE2-4A2F-BDA2-B5F800F4915E</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>270000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust-WT1 in the kidney: Regulation of the epithelial - mesenchymal balance</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>10342265-1FB9-42C3-8A98-FA28276855AD</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pfizer Ltd-Neural induction of mouse and embryonic stem cells - studentship Agnieszka Paca</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Pfizer Ltd</gtr:fundingOrg><gtr:id>1C0A2D60-2EF0-44E8-AA4D-C054BDC533B7</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>190000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Research Council (MRC)-Transfer of Millstein Award from the University of Cambri</gtr:description><gtr:end>2012-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>AFB3E00A-BF25-4DDC-90DE-9684F43F9A11</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Gamma irradiation sources for studies on stem cell and immune cell function</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>2FC94E7E-3EC6-4CDD-95CA-04DCC9631D85</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>29000</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>French Association of the Order of Malta</gtr:department><gtr:description>The Order of Malta &amp;quot;France&amp;quot;-Insights from m. Leprae-induced early demyelination: towards predictive and therapeutic targets for leprosy nerve damage/The Order of Malta &amp;quot;France&amp;quot;</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>Order of Malta</gtr:fundingOrg><gtr:id>604AD1C9-0288-40C7-884B-23B637F0532D</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2010-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Stem Cell Research Foundation (USA)</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Bedford Stem Cell Research Foundation</gtr:fundingOrg><gtr:id>EDE7853C-FFFC-4239-A7B1-96BFA94297DD</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>340000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Scottish National Blood Transfusion Service-Proof of principle: human embryonic stem cell derived red cell concentrates for clinical transfusion/Scottish National Blood Transfusion Service</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>Scottish National Blood Transfusion Service (SNBTS)</gtr:fundingOrg><gtr:id>AA5A3037-3A47-4E1B-A837-0356F53016B9</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>490000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Notch signalling in developmental specification of haematopoietic stem cells</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Melville Trust for Care and Cure of Cancer</gtr:fundingOrg><gtr:id>BC65136C-1D73-4A34-88B5-AB0C1A35BA58</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cancer Research UK-Identification of genes required for the maintenance of AML cancer stem cells</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>3A6994DE-02E8-4160-9A9A-1F84E2828943</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>270000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust-Comparative genomics of the inflammatory response</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>6865F059-D134-4CE5-9055-805A3E62B660</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University College London-Comparing and contrasting the gene expression phenotype of dopamine neurons derived from stem cells with that from the human substantia nigra/University College London</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>University College London (UCL)</gtr:fundingOrg><gtr:id>7C8AE94A-82E7-42FC-AF76-F72F2E992BCE</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of Georgia-Mechanisms controlling theymic homeostasis, involution and rebound. Core Grant/University of Georgia</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>University of Georgia</gtr:fundingOrg><gtr:id>28EB7705-6BA8-4E13-94F3-ECBDF2D0A2D1</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>219600</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leukaemia Research (Ex vivo expansion of human haematopoietic stem cells from the embryonic AGM region)</gtr:description><gtr:end>2011-04-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>074946B5-61EF-40B1-9709-77B0C5104DEE</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>516000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>European Commission (EC)-EuroStemCell: European Consortium for Communicating Stem Cell Research/euorpean commission (EC)</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>0749E3F7-080A-46C0-AF5D-6AF127C8AE10</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Analysis of cellular mechanisms underlying haematopoietic</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>5D842C30-1891-4AE0-8055-0C0ADDABFC6F</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust-Vacation Scholarship for James Beggs:</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>0E28F232-F5ED-4093-9E5B-6147C2977E5F</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>410000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Multiple Sclerosis Society-Identification of Inflammatory Cytokines that Promote Myelination and Remyelination</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Multiple Sclerosis Society</gtr:fundingOrg><gtr:id>2C6861E5-4FBF-4E7C-9B51-2B24DF2EB55C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>WT Vacation Scholarship</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>966E0939-E5EA-426F-AA1F-AA7492040BB1</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>260000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust-The Src and FAK families of non-receptor tyrosine kinases in primary brain tumours</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>6FFB1F81-6C04-407D-B53F-109E06950F06</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>VIP Award</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>80C61F49-44B1-41C7-927F-12522E7E1BD3</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Research Council (MRC)-Transcriptional regulation of hematopoietic self-renewal, lineage specification and leukemogenesis</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>094217EF-3684-40E8-B08F-E91A4CFC385A</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1530000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Research Council (MRC)-ANALYSIS OF MECHANISMS OF EARLY HAEMATOPOIETIC STEM CELL DEVELOPMENT CONTROLLED BY FLK1/SCL REGULATORY NETWORK</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>4CB8B372-C46E-4C92-8410-F1E5CDFDE2E2</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>460000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Biotechnology and Biological Sciences Research Council (BBSRC)-Integrating developmental pathways and chromatin structure during lineage specification</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>0A8B3BC2-95D0-4D91-B5BD-29B15EB2DB33</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>184858</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF Project Grant PG/05/077/18240 (Mechanisms of acclerated atherogenesis and sudden death in an ApoE-/- / 11HSD2-/- double knockout mouse) PI Dr Y V Kotelevtsev</gtr:description><gtr:end>2006-12-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>PG/05/077/18240</gtr:fundingRef><gtr:id>90AD2F09-E47F-4E78-9A9E-AC98D58CF376</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2004-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>620000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Research Council (MRC)-Strategic Appointment of Dr Nerlov</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A484895D-9C1F-4D55-A921-772EFD41CCBF</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant (G0400690)</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>7C0DA816-5C23-4720-96B4-CA9F56126D5F</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>290000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust-CAT: Morley: Novel Ligands for Fluorescent Imaging of Breast and Ovarian Cancer in Mouse Models (Brunton)</gtr:description><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>F19C768A-E9FA-4E0F-9DD4-17743A402453</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1600000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Biotechnology and Biological Sciences Research Council (BBSRC)-Identification of Functional Domains in the AGM Region linked to the hierarchical organisation of the developing haematopoietic stem cell lineage</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>CHDI Foundation</gtr:fundingOrg><gtr:id>D11E4C76-E6FB-4D1D-927D-32A256F0C823</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>220000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of Cambridge-Transfer of MS Society Grant from Cambridge: Costs for A Jarjour/University of Cambridge</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>University of Cambridge</gtr:fundingOrg><gtr:id>B2B88B79-E81D-43C2-B130-99ABDE310786</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>830000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust-Advanced FACS equipment for stemcell research</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>1993627D-BED8-4C85-99E9-FE738B672BF7</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>41000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Daphne Jackson Trust</gtr:department><gtr:description>Daphne Jackson Trust-Fellowship for Joanna Brzeszcyzynska: miRNAs role in muscle pathphysiology of cancer cachexia</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>University of Surrey</gtr:fundingOrg><gtr:id>2DB50ECE-5FE5-46BC-AF59-DD929B1E07C2</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Research Council (MRC)-ANALYSIS OF MECHANISMS OF EARLY HAEMATOPOIETIC STEM CELL DEVELOPMENT CONTROLLED BY FLK1/SCL REGULATORY NETWORK</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>2939EE34-260E-4D71-8F25-F29F47DF3A71</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF Project Grant</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>4EF7FD63-AC9F-4089-8D40-F575167408D5</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust-Structural and functional changes in the distal convoluted tubules of the kidney in mouse models of hypertension</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>3307B4AE-2568-4701-8406-0EA22C0FBA93</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>WT Society Award</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>FE87993E-9CD8-4631-BC04-BC828B8B8D69</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BEST-Stem Cells: Bio-chemically Equivalent Substitutive Technology for Stem Cells (MGMT-budget CMVM)</gtr:description><gtr:end>2012-06-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>219DBDEF-44A5-45B1-A477-F9BE94F5F8F5</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>310000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Marie Curie Initial Training Network NotchIT</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Marie Curie Actions</gtr:fundingOrg><gtr:id>4720B95C-E880-4AFC-8E9A-6FC7A390C87C</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Stem Cells Initiative Project Grant</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>CCF2CBD0-A278-4B26-819C-B4988BC5B008</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1610619</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>089000/Z/09/Z Wellcome Trust Programme Grant (Axoglial interactions during myelination in the CNS) PIs Brophy and French-Constant</gtr:description><gtr:end>2013-07-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>089000/Z/09/Z</gtr:fundingRef><gtr:id>95B02112-534D-4ACD-831B-6AE1C30CDDAC</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>32000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIH Programme Project-Mechanisms Controlling Thymic Homeostasis, Involution, and Rebound.(co applicant potion given)/NIH Programme Project</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>66869584-9D07-42BC-949B-E69F986BC266</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>410000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of Cambridge-Transfer of MRC Award from Cambridge: Integrin Engineering to Promote Axon Regeneration and Schwann Cell Migration/University of Cambridge</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>University of Cambridge</gtr:fundingOrg><gtr:id>2A807252-FA6C-4506-B1DD-CFA30E198183</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Scottish Executive Pilot Study</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>Government of Scotland</gtr:fundingOrg><gtr:id>1CF2AA9D-CC96-4FD4-9F77-A9150078993E</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2010-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>230000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust-ECAT: O'Neill: Can Mitotic Kinases be Expolited as Drug Targets in Oseophageal Adenocarcinoma? (Hupp)</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>274E540A-F295-4ECE-B2E0-E59E1DA0F1F2</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leukaemia Research Foundation-Molecular and Cellular Analysis of Thymic Epithelial Progenitor Cells</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>B79BD40E-F28B-4558-9B72-8CCAE69EF734</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>31000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of Georgia-Mechanisms controlling theymic homeostasis, involution and rebound. Core Grant/University of Georgia</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>University of Georgia</gtr:fundingOrg><gtr:id>C529F1C1-9E4C-42C7-AAEE-FB13F09ADA52</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1510000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Research Council (MRC)-Centre Grant: MRC UoE Centre for Inflammation Research</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>01DD9B39-2C63-4ADE-A446-B70D33CC1837</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Collaborative Studentship (partner Stem Cell Sciences)</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>6CA9682B-C8C9-4BBD-A1C0-660B95F21571</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>95000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Knowledge Transfer Partnership-Estimate of 2 year project between Roslin Cellab and University of Edinburgh/knowledge transfer partnership</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Technology Strategy Board (TSB)</gtr:fundingOrg><gtr:id>42B8038D-9243-4288-8A33-4F025650A477</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>180000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Generating models of hepatic endoderm from hESCs suitable for industrial application</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Stem Cells for Safer Medicines (SC4SM)</gtr:fundingOrg><gtr:id>C6CE8170-F06B-4188-86C1-357DA40A1141</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>72000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of Cambridge-Transfer of MS Society Grant from Cambridge: Costs for A Jarjour/University of Cambridge</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>Multiple Sclerosis Society</gtr:fundingOrg><gtr:id>B4DDE641-3796-4F3B-A6D4-DAD2CD52A1DA</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Royal Society/Newton International Fellowship-Pablo Navarro's Newton International Fellowship: Analysis of the gene regulatory network controlling ES cell identity</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:id>D4DDA545-2C94-47F4-A591-C7BA926563C0</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Licence - tech ID 2048 - Keisuke Kaji - Active Motif Non Exclusive April 2010</gtr:description><gtr:id>5558978A-996E-4AE5-92EE-A4A1DAB77DE0</gtr:id><gtr:impact>NK</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence - tech ID 2048 - Keisuke Kaji</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Patent - tech ID 2198 - Dave Hay/John Iredale - Polymer for hepatocyte culture - PCT</gtr:description><gtr:id>3EA81AD8-73A6-45FC-B73C-456A18896921</gtr:id><gtr:impact>NK</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2010106345 (A1)</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Patent - tech ID 2198 - Dave Hay/John Iredale</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Apoptotic bodies for the generation of noval Abs for monoclaonal therapy</gtr:description><gtr:id>220EE07F-DCB7-44CD-B42D-BEFB83E353A2</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Apoptotic bodies for the generation of noval Abs for monoclaonal therapy</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence under negotiation - tech ID 2048 - Keisuke Kaji Active Motif Non-exclusive Field of use - Development of research reagents</gtr:description><gtr:id>013B8DB8-48E8-4E4C-A9A2-89857C7744DF</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence under negotiation - tech ID 2048 - Keisuke Kaji</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence - tech ID 2048 - Keisuke Kaji - Active Motif Non Exclusive Feb 2010</gtr:description><gtr:id>198F8060-5E06-408A-BA37-D19DC9E5D8B7</gtr:id><gtr:impact>NK</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence - tech ID 2048 - Keisuke Kaji</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence - tech ID 2388 - Brendon Noble - Gernon Corporation - Field Exclusive</gtr:description><gtr:id>0D78A63C-1BA2-49A0-8B4D-75CE48F0FD09</gtr:id><gtr:impact>NK</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence - tech ID 2388 - Brendon Noble</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Patent - tech ID 490 - Ian Chambers - Pluripotency determining factors (Nanog) - National</gtr:description><gtr:id>66B0FE11-00CA-4F1A-8F10-AE0CACE06409</gtr:id><gtr:impact>NK</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO03064463 (A2)</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Patent - tech ID 490 - Ian Chambers</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Patent - tech ID 1084 - Josh Brickman - Regionalised endoderm cells and uses thereof - National</gtr:description><gtr:id>8F0B30CB-833C-490D-B57F-5B08C273D527</gtr:id><gtr:impact>NK</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>EP2195417 (A1)</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Patent - tech ID 1084 - Josh Brickman</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Primary screen to identify compounds to treat cirrhosis of the liver</gtr:description><gtr:id>570DC11A-8951-4CDB-A2B7-EF6E4ECCC82B</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Primary screen to identify compounds to treat cirrhosis of the liver</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence - tech ID 254 - J A Ross - Santa Cruz Non-exclusive</gtr:description><gtr:id>0BB67757-2B0F-46D5-92E1-AB090E697A14</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence - tech ID 254 - J A Ross</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Polymers for joint capping</gtr:description><gtr:id>A64C1008-451E-46C4-8A50-3A438A7EAEDD</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Polymers for joint capping</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Pluripotent cells are derived and maintained in a self-renewing state in serum-free culture medium comprising a MEK inhibitor, a GSK3 inhibitor and an antagonist of an FGF receptor.
Also published as EP2049654</gtr:description><gtr:id>4EAA6A3B-33E1-4095-9972-4871265EA475</gtr:id><gtr:impact>Not known</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>US2008066197</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Pluripotent cells from rat and other species</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence under negotiation - tech ID 2398 - David Hay/John Iredale - Primorigen Biosciences - Evaluation</gtr:description><gtr:id>EDD3777E-1AFE-4B1F-80FE-5D249111C6DE</gtr:id><gtr:impact>NK</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence under negotiation - tech ID 2398 - David Hay/John Iredale</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Patent - tech ID 1084 - Josh Brickman - Endoderm Culture Type PCT</gtr:description><gtr:id>D033D8AF-0C20-470C-BC82-AFF84260B687</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Patent - tech ID 1084 - Josh Brickman</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A gene trap vector comprises a DNA construct containing an expression unit of an internal ribosome binding site (IRES) coupled to a heterologous gene sequence; this expression unit is used in gene trap protocols to obtain expression of the heterologous gene in the host.</gtr:description><gtr:id>103709EE-394D-4DC1-8BCE-DC1FE687CCD4</gtr:id><gtr:impact>Not known</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>JP2007306942</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Expression of heterologous genes according to a targeted expression profile</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Novel method of hepatocyte differentiation form IPS cells</gtr:description><gtr:id>6B4E3409-8FC4-433D-AA34-F6388AA14F26</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Novel method of hepatocyte differentiation form IPS cells</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence - tech ID 2048 - Keisuke Kaji - iPerian, Inc Evaluation</gtr:description><gtr:id>756BC806-8D32-4105-AC97-0C530701BA34</gtr:id><gtr:impact>NK</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence - tech ID 2048 - Keisuke Kaji</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Development of creation of induced Pluripotent Stem Cells by introducing the apporiate genes using a non-viral plasmid -based method, which can be removed once the pluripotent cells have been generated.</gtr:description><gtr:id>CFB29E7B-2AFC-4580-A927-E7E75E9042D7</gtr:id><gtr:impact>Interest from commercial companies</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Safely creating induced pluirpotent stem cells</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence under negotiation - tech ID 2048 - Keisuke Kaji Mitergy LLC Evaluation licence Field of use - internal evaluation</gtr:description><gtr:id>94AEBFD0-CE8B-453B-AC92-81D6DC38E14B</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence under negotiation - tech ID 2048 - Keisuke Kaji</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>High throughput method for screening gene target</gtr:description><gtr:id>A86CD41C-49FC-46F2-BDCE-EECAE1D21AD1</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>High throughput method for screening gene target</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>MRCT (CRB): Anti-mullerian Hormone</gtr:description><gtr:id>D115AD2B-E461-4008-974A-FA4821D47C16</gtr:id><gtr:impact>NK</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Disclosure</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>HA (800 000 D) as hESC substrate supports renewal</gtr:description><gtr:id>1C829180-2260-406B-A476-C16EB56582FF</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>HA (800 000 D) as hESC substrate supports renewal</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Plet 1 Antibodies</gtr:description><gtr:id>860BF9CC-E820-426E-BE6B-47A4002460D8</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Plet 1 Antibodies</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A method for generating a culture that is purified or enriched in respect of cells of a selected lineage is described in which selectable marker, which is differentially expressed in cells of the selected lineage compared with its expression in other cells, is introduced into a multipotential cell and the multipotential cell is cultured to induce differentiation of the multipotential cell into a cell of the selected lineage, or into a mixture of cells including cells of the selected lineage, or is cultured to induce preferential survival of cells of the selected lineage. Those cells that express the selectable marker are then selected for. Progenitors of selected lineage are also described as is the use of the method in assay techniques.</gtr:description><gtr:id>44FFE68E-6902-46E3-8CE5-CFC367409CB8</gtr:id><gtr:impact>None known</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>US2007264709</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Lineage specific cells and progenitor cells</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence - tech ID 2048 - Keisuke Kaji - Adgene Non-exlcusive</gtr:description><gtr:id>4922DECB-B3F3-43AD-A818-D38A109F7246</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence - tech ID 2048 - Keisuke Kaji</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Patent - tech ID 2048 - Kaji Keisuke - Induced Pluripotent Stem Cells Type - PCT</gtr:description><gtr:id>257D052E-05E1-45F5-9B9A-5BDFD91DA1F1</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Patent - tech ID 2048 - Keisuke Kaji</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Patent - tech ID 2108 - Paul de Sousa - Method for differentiating stem cells Type - Priority</gtr:description><gtr:id>370DEC23-8F3C-4C97-8856-A7FEC174CCDA</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Patent - tech ID 2108 - Paul de Sousa</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence under negotiation - tech ID 2048 - Brendon Noble - To make therapeutics - Exclusive</gtr:description><gtr:id>4E6E7F88-64D0-4973-B82E-92121481D28D</gtr:id><gtr:impact>NK</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence under negotiation - tech ID 2048 - Brendon Noble</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence - tech ID 928 - Keisuke Kaji - European Collection of Cell Cultures - Non-Exclusive</gtr:description><gtr:id>544A605A-7BC3-4D6C-87E8-F323F996DD7A</gtr:id><gtr:impact>NK</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence - tech ID 928 - Keisuke Kaji</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>RXR agonists to promote remylination</gtr:description><gtr:id>15AFD967-013D-4E30-AB82-E2C280F83A4B</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>RXR agonists to promote remylination</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Production of transplantable haematopoietic stem cells</gtr:description><gtr:id>B6C38165-9D3F-4C02-A3BA-0BAC019FFD2C</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Copyrighted (e.g. software)</gtr:protection><gtr:title>Production of transplantable haematopoietic stem cells</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Frzb role in hematopoietic differentiation</gtr:description><gtr:id>0C3AD059-5AA7-4866-8764-D3AD6B62F28D</gtr:id><gtr:impact>NK</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Disclosure</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Embedded licence in SC4SM contract</gtr:description><gtr:id>2F5C8828-F757-48E6-A80A-20AD37FA8C44</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Embedded licence in SC4SM contract</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence under negotiation - tech ID 2198 - Mark Bradley Stemgent Evaluation licence Field of use - in discussion</gtr:description><gtr:id>A68B2D62-7322-4F6D-8045-A04F479215B1</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence under negotiation - tech ID 2198 - Mark Bradley</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence - tech ID 2048 - Keisuke Kaji - Hematech Inc Evaluation</gtr:description><gtr:id>82881B5C-5424-4401-A8D2-2729B7811029</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence - tech ID 2048 - Keisuke Kaji</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence under negotiation - tech ID 2048 - Keisuke Kaji - Stemgent Non-Exclusive Feild of use - Research reagents</gtr:description><gtr:id>533AFBC9-6F26-4B2F-8512-A67C47121D7D</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence under negotiation - tech ID 2048 - Keisuke Kaji</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence under negotiation - tech ID 1084 - Josh Brickman - evaluate use to make research reagents with view to take an exclusive licence - Evaluation</gtr:description><gtr:id>15136512-0DF6-4708-9593-37A42660BD9F</gtr:id><gtr:impact>NK</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence under negotiation - tech ID 1084 - Josh Brickman</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Identification of a novel polymer which provides a solution to poor quality cells</gtr:description><gtr:id>322AA035-0116-419B-B29F-C113671756E8</gtr:id><gtr:impact>Discussion with commercial companies in progress</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Novel Polymers for culturing liver cells</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Novel method for producing hepatocytes from IPS cells</gtr:description><gtr:id>44391ED5-B5EC-4278-BA5B-F4C2B1F4AD45</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Novel method for producing hepatocytes from IPS cells</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Biodegradable Encapsulates for Affinity Targeted (BEAT) Technology in Stem Cell Culture and Regenerative Medicine</gtr:description><gtr:id>1C578F83-CABA-4B58-BDE9-B1B6D3D6086F</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Disclosure</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to the generation of transgenic animal cells and/or animals in which a large portion of a host animal's genome has been replaced with an equivalent syntenic portion of nucleic acid from the genome of a different organism.</gtr:description><gtr:id>9736C494-279C-4926-A9C9-C310A0A3F098</gtr:id><gtr:impact>Not known</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>EP2099289</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>HUMANISATION OF ANIMALS</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence - tech ID 1084 - Josh Brickman - Geron Corporation Evaluation</gtr:description><gtr:id>2929E7FA-B483-4A4B-A469-A41025E6C6C8</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence - tech ID 1084 - Josh Brickman</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Dextransulphate a novel reagent for stem cell differentiation</gtr:description><gtr:id>3C8C0769-5A72-4233-92CF-F5E68906A0B4</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Dextransulphate a novel reagent for stem cell differentiation</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence - tech ID 1023 - Andrew Smith - Astra Zeneca Non-exclusive</gtr:description><gtr:id>9290C302-6A24-4DC5-89AD-66DBEA49AAC2</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence - tech ID 1023 - Andrew Smith</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Lithium Chloride as a novel reagent to promote stem cell differentiation into bone</gtr:description><gtr:id>29F03D5D-AB81-4D7E-BE3E-D2E41EA2357B</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Lithium Chloride as a novel reagent to promote stem cell differentiation into bone</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Novel Relaxin Mimetic</gtr:description><gtr:id>8F89ECD6-3F9B-4030-8742-A5938680BE83</gtr:id><gtr:impact>NK</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Disclosure</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Cellular therapy to treat cirrhosis of the liver</gtr:description><gtr:id>502327C0-E834-4AA1-8AA9-322424B1F0EE</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Cellular therapy to treat cirrhosis of the liver</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Patent - tech ID 2108 - Paul de Sousa - Method for differentiating stem cells Type - PCT</gtr:description><gtr:id>D0859BD8-A576-461F-8C1C-B7AD682A0D3F</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Patent - tech ID 2108 - Paul de Sousa</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Patent - tech ID 859 - Andrew Smith - Humanisation of Animals - National</gtr:description><gtr:id>FF6875E3-385E-4E5A-A7F0-2EF801780A76</gtr:id><gtr:impact>NK</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>US2010122361 (A1)</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Patent - tech ID 859 - Andrew Smith</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Patent - tech ID 2388 - Brendon Noble -Novel method for chondrocyte formation - Priority</gtr:description><gtr:id>3B4E5D80-4EB2-4AC8-A1C6-B632ECAEF880</gtr:id><gtr:impact>NK</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>US2011256109</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Patent - tech ID 2388 - Brendon Noble</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence under negotiation - tech ID 2048 - Keisuke Kaji iPerian, Inc Evaluation licence Field of use - internal evaluation</gtr:description><gtr:id>7F01E05F-81D8-4839-9B5D-21FCC9D04B9F</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence under negotiation - tech ID 2048 - Keisuke Kaji</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence - tech ID 223 - J A Ross - Santa Cruz Non-Exclusive</gtr:description><gtr:id>83582EA3-CCA1-4BEA-9D29-61368D129E66</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence - tech ID 223 - J A Ross</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Hepatocyte differentiation media</gtr:description><gtr:id>BD7030B5-49D2-43BB-91DB-06F0A4FD0905</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Hepatocyte differentiation media</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Embedded licence: HESC Blood project</gtr:description><gtr:id>2FB508F5-543F-4CD4-AD2E-BC094E81FB86</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Embedded licence: HESC Blood project</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>ES Cell self renewal factor</gtr:description><gtr:id>53D10D98-E1DD-4B6F-B991-B010E1A5B72D</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>ES Cell self renewal factor</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Self renewal of pluripotent cells in culture is promoted using a combination of an activator of a signalling pathway downstream of a receptor of the TGF-beta superfamily and an activator of a gp130 downstream signalling pathway. 
Also published as KR20070030164</gtr:description><gtr:id>2E77E6B3-C837-4F85-A13D-AC0970732520</gtr:id><gtr:impact>Not known</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>JP2008228742</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Control of ES Cell Self Renewal and Lineage Specification, and Medium Therefor</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Anterior definitive endoderm 11</gtr:description><gtr:id>75DBD73C-FB39-43D9-8F80-29C079FDE0AA</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Anterior definitive endoderm 11</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>New method of production of glioma neural stem cell lines from tumours</gtr:description><gtr:id>140FE606-08B4-4E63-A422-9650A5E1F035</gtr:id><gtr:impact>Discussion with commercial companies in progress</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Glioma-dervided Neuronal Stem Cell Lines for Screening</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence - tech ID 2127 - Josh Brickman - Stem Cells 4 Safer Medicine Limited Non-Exclusive</gtr:description><gtr:id>B6C43F40-2CCE-46D8-95F2-F1B4CA1D34F5</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence - tech ID 2127 - Josh Brickman</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Retinoid independent and accelerated generation of functional motor neurons from human embryonic stem cells</gtr:description><gtr:id>ACB9CD7B-DB08-4007-BF8B-171876DF2C1D</gtr:id><gtr:impact>NK</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Disclosure</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Transgenic mice for studying the haemotpoetic system</gtr:description><gtr:id>6D22DF4E-4380-4B02-81D2-A14734457426</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Disclosure</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence - tech ID 1023 - Andrew Smith - Charles River Laboratories, Inc. Field Exclusive</gtr:description><gtr:id>CA893B96-BF83-4B83-8C42-4FD83EAAB0A3</gtr:id><gtr:impact>NK</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence - tech ID 1023 - Andrew Smith</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Patent - tech ID 859 - Andrew Smith - Genome replacement technology Type - National</gtr:description><gtr:id>E60544A4-8310-4BA1-B494-0497F42040E5</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Patent - tech ID 859 - Andrew Smith</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Method for differentiating stem cells</gtr:description><gtr:id>BFD8F182-D8B7-4B19-9616-FEFBF32BA062</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Method for differentiating stem cells</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Methods for reprogramming and optional genetic modification of cells are provided. A pluripotent genome is obtained from a differentiated genome by fusing a pluripotent cell with a differentiated cell in the presence of Nanog or a MEK inhibitor. A cell is genetically modified by providing first and second cells, each containing chromosomes, fusing the first cell and the second cell, and culturing the fused cell so as to obtain a diploid cell containing at least one chromosome from the first cell and at least one chromosome form the second cell. A method of cell fusion comprises fusing a first cell and a second cell in the presence of Nanog or a MEK inhibitor. Cells obtained thereby and their uses are also described.</gtr:description><gtr:id>5F19E01D-AEC8-4BB0-9366-38C29F251931</gtr:id><gtr:impact>Not known</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2007054720</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>REPROGRAMMING AND GENETIC MODIFICATION OF CELLS</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence - tech ID 223 &amp;amp; 254 - J A Ross - Millipore Corporation Non-Exclusive</gtr:description><gtr:id>7E7D0D4A-B2A6-4142-96E3-D6CC5D0B8232</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence - tech ID 223 &amp;amp; 254 - J A Ross</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Development of a novel mehof of culture and differentiaation of embryonic stem cells that will enable derivation and exapansion of HSCs in vitro.</gtr:description><gtr:id>DEBD5FAF-6CD6-44B8-A156-B60C5A7B75C1</gtr:id><gtr:impact>NK</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Improving options for bone marrow transplants</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence under negotiation - tech ID 2048 - Keisuke Kaji - to humanise mouse models.- Non-Exclusive</gtr:description><gtr:id>EFB2D685-982E-4545-AD69-A3388102249B</gtr:id><gtr:impact>NK</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence under negotiation - tech ID 2048 - Keisuke Kaji</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Use of sonication enhancement (contrast) agents for killing bacteria James Ross</gtr:description><gtr:id>2391B22A-E32E-45E1-A650-7349358D27E0</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Use of sonication enhancement (contrast) agents for killing bacteria</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Patent - tech ID 2108 - Paul de Sousa - Method for differentiating stem cells Type - National</gtr:description><gtr:id>0A48E1CA-98BE-454D-B5ED-49152154DBF0</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Patent - tech ID 2108 - Paul de Sousa</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence under negotiation - tech ID 2048 - Keisuke Kaji - Evaluation of iPS cell lines- Non-Exclusive</gtr:description><gtr:id>536D419D-B057-4E92-A9A1-58A91806A208</gtr:id><gtr:impact>NK</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence under negotiation - tech ID 2048 - Keisuke Kaji</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Patent - tech ID 2110 - Paul de Sousa - HA (800 000 D) as hESC substrate supports renewal Type - PCT</gtr:description><gtr:id>37F48707-2F31-4F61-A011-2C9D79B5045F</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Patent - tech ID 2110 - Paul de Sousa</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Pluripotent cells are maintained in a self-renewing state in serum-free culture medium comprising a MEK inhibitor, a GSK3 inhibitor and, optionally, an antagonist of an FGF receptor. Pluripotent cells are also maintained in a self-renewing state in serum-free culture medium comprising a MEK inhibitor and an antagonist of an FGF receptor. 
Also published as EP1999249</gtr:description><gtr:id>CC633C8E-9ED7-4026-82CA-896D94E79B22</gtr:id><gtr:impact>Not known</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>US2010041137</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>CULTURE MEDIUM CONTAINING KINASE INHIBITORS, AND USES THEREOF</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Regionalised Endoderm cells and uses thereof</gtr:description><gtr:id>7E380E47-CF60-4176-BE70-CEB91A90F4B4</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Copyrighted (e.g. software)</gtr:protection><gtr:title>Regionalised Endoderm cells and uses thereof</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence - tech ID 1023 - Andrew Smith - Novartis AG Non-exclusive</gtr:description><gtr:id>3381F117-158B-4880-A47A-E1443FFC04FC</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence - tech ID 1023 - Andrew Smith</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Patent - tech ID 2110 - Paul de Sousa - HA (800 000 D) as hESC substrate supports renenwal Type - Priority</gtr:description><gtr:id>AA7D66B0-5CE6-46AF-B307-2B5400E2E8FD</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Patent - tech ID 2110 - Paul de Sousa</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence under negotiation - tech ID 2398 - David Hay/John Iredale - Cellartis AB - Evaluation</gtr:description><gtr:id>F15F6F5F-A376-4FDD-8AB3-30E6FD296A85</gtr:id><gtr:impact>NK</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence under negotiation - tech ID 2398 - David Hay/John Iredale</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Human platelet lysates for human cartilage formation</gtr:description><gtr:id>C343EE37-6FC6-4C9B-AA8B-516A070B7025</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Human platelet lysates for human cartilage formation</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence - tech ID 2119 - Clare Blackburn - Millipore Corporation Non-Exclusive</gtr:description><gtr:id>7151178B-5BB6-42D5-A0A2-57B8AA70E86E</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence - tech ID 2119 - Clare Blackburn</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Stimulation of human embryonic stem ES cells to generate a limitless source of mature, oxygen-carrying red blood cells</gtr:description><gtr:id>EA2A1CA7-55F6-475D-8EDE-6A6E5236EC6F</gtr:id><gtr:impact>Working with SNBTS, Unviersity of Glasgow, NHS Blood &amp;amp; transplant, the Irish Blood transfusion Service and Roslin Cells Ltd.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Using embryonic stem cells to generate red blood cells for clinical transfusion</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Glycocalyx</gtr:description><gtr:id>53D3039E-BFC3-41A1-9069-492A55B715D8</gtr:id><gtr:impact>NK</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Disclosure</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence - tech ID 2317 - Lesley Forrester - SNBTS Exclusive</gtr:description><gtr:id>1514B8D6-43D7-4C56-A6B2-B96CA7771D45</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence - tech ID 2317 - Lesley Forrester</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Licence under negotiation - tech ID 2048 - Keisuke Kaji - Company requested exclusive licence for research reagents and therapeutics. UoE thinks non-exclusive is more appropriate. Scope of licence and field of use under discussion.- Non-Exclusive</gtr:description><gtr:id>0ABE703B-2971-4BEA-A44F-E5234746CBED</gtr:id><gtr:impact>NK</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licence under negotiation - tech ID 2048 - Keisuke Kaji</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Production of an efficient and effective culture method for purifying intermediate in vitro-derived ADE cells from embryonic stem cells</gtr:description><gtr:id>A3FB42FB-A247-4365-B035-5690E93252F7</gtr:id><gtr:impact>Currently available to companies</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Cell Culture Methods to Produce ADE Cells</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>BMJ Editorial on stem cells in MS, 2010</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>F81EDC85-F4F5-4995-8DCC-4C52DD452F25</gtr:id><gtr:impact>NK</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Characterisation of large pre-existing hybridoma panel on human and zebrafish embryonic tissue, funding in place from Bioquarter (UoE/SE) to characterise antibodies particularly with regard to those recognising lineage markers in zebrafish, antibodies to be freely available to zebrafish community and hybridomas to be licensed by UoE.</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>DBD517BB-695B-4F72-B09E-63D898FCE1F5</gtr:id><gtr:impact>antibodies to be freely available to zebrafish community and hybridomas to be licensed by UoE. Possible contribution to spin-out company from UoE</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>CFFC - gave presentation at workshop on Regenerative Medicine at the House of Lords, 23rd Oct, Charles ffrench-Constant</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BC597C96-891A-45EC-A35A-809D49060D9F</gtr:id><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Monthly MS Discussion Group for Neurologists in SE Scotland</gtr:description><gtr:geographicReach>Local/Municipal/Regional - UK Only</gtr:geographicReach><gtr:id>A2E16A52-500B-4299-A0C7-BF210F5D7BF9</gtr:id><gtr:impact>Discussion of clinical cases, current research etc. 2008-continues. Very successful in providing clinical support, propagating important research findings and general clinical policies throughout our catchment area.</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Wellcome ERG</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>E5B29DED-2D78-4481-BB0E-879C6FBE1A97</gtr:id><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Inverkeithing High School and others very keen to repeat the SSCN roadshow and for it to become a regular part of the school's commitment to the curriculum for excellence</gtr:description><gtr:geographicReach>Local/Municipal/Regional - UK Only</gtr:geographicReach><gtr:id>2BB08943-0749-474F-BA8B-410E429B626B</gtr:id><gtr:impact>Public outreach</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Development of multi-modal contrast agents for imaging and gene delivery</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>47DC693E-6B0A-41FB-9CAD-7F9E5F0B6CAD</gtr:id><gtr:impact>available to research community, collaborators in Edinburgh include CVS, CRB</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Participation in British Council funded Latin America PhD student course 'ES cells as a model system for embryonic development' in Sao Paulo, Brazil [February 2009].</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>89083F45-7198-4A97-A5DA-EBEF6B6EF338</gtr:id><gtr:impact>NK</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Book chapter on human-animal chimeras, collaboration with Neville Cobbe.</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>25EB38A0-C171-4D4D-9E8F-FA5A7C8E6F14</gtr:id><gtr:impact>NK</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Scientific Advisory Board for the Scottish Universities Environmental Research Centre (SUERC)</gtr:description><gtr:geographicReach>Local/Municipal/Regional - UK Only</gtr:geographicReach><gtr:id>A2A80ED6-1A97-48C7-A3B7-5049F17D3846</gtr:id><gtr:impact>Appointed to the Scientific Advisory Board for the Scottish Universities Environmental Research Centre (SUERC) from 2010.</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Research materials.</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>DAE57DD6-8C3E-48CA-A2DD-CBBB5C8A9DDF</gtr:id><gtr:impact>Research materials.</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Myelinating co-culture technologies</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>90F3AD86-3F43-4A41-99E5-B635A07F9EBB</gtr:id><gtr:impact>Myelinating co-culture technologies, for which we receive at least one request/month for protocols or training</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Prevalence register for patients in Scotland.</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>CEBE2DC3-634C-422D-962B-22A6296DAE12</gtr:id><gtr:impact>Have contributed to the momentum that led to the Scottish Governments agreement to fund a prevalence register for patients in Scotland.</gtr:impact><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>DNA vectors</gtr:description><gtr:id>2BCACA20-977B-4118-85F0-FC8127DF9215</gtr:id><gtr:impact>NK</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>DNA vectors</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We developed a culture system of embryonic AGM region cells which after reaggregation resume generation of the HSC development. This enables analysis of of individual cell populations in HSC development to be performed.</gtr:description><gtr:id>0088F666-1F77-4ED0-A792-09DE3157A4F7</gtr:id><gtr:impact>Elucidating the mechanisms underlying HSC specification and expansion in the embryo have been hampered by the lack of analytical cell culture systems that recapitulate in vivo development. We developed a novel ex vivo model that facilitates a rapid and robust emergence of multipotent longterm repopulating HSCs in the embryonic AGM region and enables analysis of individual cell populations involved in this process to be performed. Using this model, we established the identity of preHSCs which mature into definitive HSCs. The importance of this study is dual i) it will shed light on one of the central problems of HSC biology, namely, genetic regulation of early HSC development and ii) provide mechanistic data for potential development of clinically relevant protocols aiming to enhance production of haematopoietic progenitors and stem cells in vitro.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Novel ex vivo HSC generation system</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>a single non-viral reprogramming vector, encoding c-Myc, Klf4, Oct4, Sox2 and mOrange</gtr:description><gtr:id>8CC9C877-3A6B-42C1-ACD5-7D608CC3563A</gtr:id><gtr:impact>It allowed the generation of induced pluripotent stem cells without viral vectors</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>pCAF2LMKOSimO</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Microarray gene expression profile of inflammation in retina, provided to myelin biology consortium based in San Francisco, part of submitted manuscript</gtr:description><gtr:id>8D0DD93A-19EF-4333-A7EF-058BBE2E915C</gtr:id><gtr:impact>provided to myelin biology consortium based in San Francisco, part of submitted manuscript</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Microarray gene expression profile of inflammation in retina</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>These transgenic mice allow upregulation of short and long Runx1 isoforms in mice</gtr:description><gtr:id>68B7C507-7B7A-4BBA-B2E5-A6CAE62A9AE3</gtr:id><gtr:impact>These mice were analysed by our collaborators which resulted in publication: Aldskogius, et al . &amp;quot;Regulation of Boundary Cap Neural Crest Stem Cell Differentiation after Transplantation&amp;quot; Stem Cells 27, 15921603</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Tetracyclineinducible Runx1 (short and long isoform) transgenic mice</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>mouse iPS cell lines, generated via pCAG2LMKOSimO</gtr:description><gtr:id>D96693DE-94C9-4966-9AF0-F1254FFFA71B</gtr:id><gtr:impact>ecause reprogramming factors(Oct4, Sox2, Klf4 and c-Myc) had been excised from the iPSC lines using Cre-recombinase, we do not need to worry about influence of exogenous factors which remain in iPSCs generated with retroviral vectors.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Non-viral iPSC lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Involved in setting up of the IHMED MS database for both research and clinical care of MS patients.</gtr:description><gtr:id>79859F4A-EBDB-46C4-8418-A2FA3212AD30</gtr:id><gtr:impact>nk</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>IHMED MS database</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A multifunctional reversible knockout/ reporter system enabling fully functional reconstitution of the AML1/Runx1 locus and rescue of haematopoiesis</gtr:description><gtr:id>E6731C4B-88BB-4A1D-A362-CAA828079126</gtr:id><gtr:impact>Analysis of these mice was an important tool used in publication: N. Stifaniet al(2008) &amp;quot;Suppression of interneuron programs and maintenance of selected spinal motor neuron fates by the transcription factor AML1/Runx1. Proc Natl Acad Sci USA 105, No 17, 64516456</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Runx1 reversible knockout/ reporter mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Development of optical coherence phase microscope (available at SEE)</gtr:description><gtr:id>3C12D606-168F-459D-BB49-91BF021D7B2B</gtr:id><gtr:impact>available at SEE,</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Development of optical coherence phase microscope</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Development of a Fourier domain optical coherence tomography instrument (available at SEE, Used by prof. Davis group, Prof. Tabrizian group)</gtr:description><gtr:id>B61143B9-7B8F-4984-8D35-F1EC684E97F5</gtr:id><gtr:impact>available at SEE, Used by prof. Davis group, Prof. Tabrizian group</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Development of a Fourier domain optical coherence tomography instrument</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Myelinating co-culture systems to analyse effects of signalling molecules on myelination, have trained visiting scientists from Holland and Portugal, essential part of work in Nature Neuroscience</gtr:description><gtr:id>BEC16567-89EB-4178-8482-53899C1D5CA6</gtr:id><gtr:impact>have trained visiting scientists from Holland and Portugal, essential part of work in Nature Neuroscience</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Myelinating co-culture systems to analyse effects of signalling molecules on myelination</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Remyelinating CNS slice culture system. Semi-automated system to study and measure remyelination in CNS ex vivo cultures.</gtr:description><gtr:id>2202A22F-DA13-48C0-9E68-7193A0DA925D</gtr:id><gtr:impact>Paper submitted to the journal &amp;quot;Brain&amp;quot;. Method taught to lab in Glasgow. Interest from company called Vaccinex, in the US.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Remyelinating CNS slice culture system</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>the method for purification of transcription factors developed in collaboration with R.Poot and detailed in paper van den Berg, D.L.C., Snoek, T., Mullin, N.P., Yates, A., Bezstarosti, K., Demmers, J. Chambers, I. and Poot, R.A. (2010) An Oct4-centred protein interaction network in embryonic stem cells. Cell Stem Cell, 6, 369-381. is a major advance in the field and we expect this to be widely taken up.</gtr:description><gtr:id>96865977-5D0E-42DB-8939-0AC823187199</gtr:id><gtr:impact>Expectation that this will be widely taken up</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>purification of transcription factors</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Gene targeted Human ES cell reporter lines (OC-4, SOX-2, KLF-4) provided to Sheffield (Peter Andrews) and Cambridge (Austin Smith) as part of ESTOOLS Consortium Project.</gtr:description><gtr:id>AC947AD6-8600-41A4-9FFC-B4A747B7C0FD</gtr:id><gtr:impact>provided to Sheffield (Peter Andrews) and Cambridge (Austin Smith)</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Gene targeted Human ES cell reporter lines (OC-4, SOX-2, KLF-4)</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Methods for label-free real-time monitoring of stem cell differentiation with electric-cell impedance sensing (available in the centre, provided to Paul de Sousa Group, Dr Hay group)</gtr:description><gtr:id>FAB28F96-B259-4003-BBBA-01B05DB364A2</gtr:id><gtr:impact>available in the centre, provided to Paul de Sousa Group, Dr Hay group</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Methods for label-free real-time monitoring of stem cell differentiation with electric-cell impedance sensing</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2BD67E87-7376-482E-A74A-02685452CBF9"><gtr:id>2BD67E87-7376-482E-A74A-02685452CBF9</gtr:id><gtr:title>A decade of progress since the birth of Dolly.</gtr:title><gtr:parentPublicationTitle>Reproduction, fertility, and development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3dddf5e8ad5ac72055f12939fbd7b06f"><gtr:id>3dddf5e8ad5ac72055f12939fbd7b06f</gtr:id><gtr:otherNames>Wilmut I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1031-3613</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/36580DF4-BCB8-4285-8359-5BAD199B49F7"><gtr:id>36580DF4-BCB8-4285-8359-5BAD199B49F7</gtr:id><gtr:title>Anterior definitive endoderm from ESCs reveals a role for FGF signaling.</gtr:title><gtr:parentPublicationTitle>Cell stem cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/99483d8330748704a10568834cf1dd4b"><gtr:id>99483d8330748704a10568834cf1dd4b</gtr:id><gtr:otherNames>Morrison GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1875-9777</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1075E787-3A6A-4D2F-B475-6E37A61A1EBE"><gtr:id>1075E787-3A6A-4D2F-B475-6E37A61A1EBE</gtr:id><gtr:title>NMD is essential for hematopoietic stem and progenitor cells and for eliminating by-products of programmed DNA rearrangements.</gtr:title><gtr:parentPublicationTitle>Genes &amp; development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4eb65dedf192af4d7f111f932bb2fa18"><gtr:id>4eb65dedf192af4d7f111f932bb2fa18</gtr:id><gtr:otherNames>Weischenfeldt J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0890-9369</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AAFF6A85-30EF-48E2-9754-B14E9B0A6962"><gtr:id>AAFF6A85-30EF-48E2-9754-B14E9B0A6962</gtr:id><gtr:title>Online monitoring of collagen fibre alignment in tissue-engineered tendon by PSOCT.</gtr:title><gtr:parentPublicationTitle>Journal of tissue engineering and regenerative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/89b43532ee93cad08e2b8bcee6f7a992"><gtr:id>89b43532ee93cad08e2b8bcee6f7a992</gtr:id><gtr:otherNames>Ahearne M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1932-6254</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8EDBEDBD-A53C-4813-A16D-D79BB5910B8F"><gtr:id>8EDBEDBD-A53C-4813-A16D-D79BB5910B8F</gtr:id><gtr:title>Variations in humanized and defined culture conditions supporting derivation of new human embryonic stem cell lines.</gtr:title><gtr:parentPublicationTitle>Cloning and stem cells</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7383d1458ff439483f8019cdc75827f4"><gtr:id>7383d1458ff439483f8019cdc75827f4</gtr:id><gtr:otherNames>Fletcher JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1536-2302</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D1D296FC-714F-409D-B274-79C5C423F447"><gtr:id>D1D296FC-714F-409D-B274-79C5C423F447</gtr:id><gtr:title>A new title and a new focus: Cellular Reprogramming.</gtr:title><gtr:parentPublicationTitle>Cellular reprogramming</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3dddf5e8ad5ac72055f12939fbd7b06f"><gtr:id>3dddf5e8ad5ac72055f12939fbd7b06f</gtr:id><gtr:otherNames>Wilmut I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>2152-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4F78024F-7117-4DAA-B8AE-4D90F4A8E1D0"><gtr:id>4F78024F-7117-4DAA-B8AE-4D90F4A8E1D0</gtr:id><gtr:title>Remyelination in the CNS: from biology to therapy.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d469ddfcd9562b3972ffe34f974f7d21"><gtr:id>d469ddfcd9562b3972ffe34f974f7d21</gtr:id><gtr:otherNames>Franklin RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1471-003X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/903600F2-152D-45BE-9227-7F137721C1E3"><gtr:id>903600F2-152D-45BE-9227-7F137721C1E3</gtr:id><gtr:title>Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a56968757a4a432b25b9465e1062905b"><gtr:id>a56968757a4a432b25b9465e1062905b</gtr:id><gtr:otherNames>Graupera M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CE2CA7E2-787F-46CE-B36E-FA14C0EDA2EA"><gtr:id>CE2CA7E2-787F-46CE-B36E-FA14C0EDA2EA</gtr:id><gtr:title>Transposon-mediated BAC transgenesis in human ES cells.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c230ffab60369848ab7c6f4f2ec18316"><gtr:id>c230ffab60369848ab7c6f4f2ec18316</gtr:id><gtr:otherNames>Rostovskaya M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6823F9C2-73C0-463A-8F43-2F22CC2D501D"><gtr:id>6823F9C2-73C0-463A-8F43-2F22CC2D501D</gtr:id><gtr:title>Cloning and expression of sheep DNA methyltransferase 1 and its development-specific isoform.</gtr:title><gtr:parentPublicationTitle>Molecular reproduction and development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4a209535e7da79b5d62367bda05695b6"><gtr:id>4a209535e7da79b5d62367bda05695b6</gtr:id><gtr:otherNames>Taylor J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1040-452X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B1AC131A-EF1A-4CFE-B11C-EE9F3FA5E77D"><gtr:id>B1AC131A-EF1A-4CFE-B11C-EE9F3FA5E77D</gtr:id><gtr:title>The inhibitory role of stromal cell mesenchyme on human embryonic stem cell hepatocyte differentiation is overcome by Wnt3a treatment.</gtr:title><gtr:parentPublicationTitle>Cloning and stem cells</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6bd387f55c76db9e99830d4f5107988c"><gtr:id>6bd387f55c76db9e99830d4f5107988c</gtr:id><gtr:otherNames>Fletcher J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1536-2302</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700711</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>